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Abstract
The co-occurrence of psychotic symptoms and Alzheimer’s disease (AD) is a devastating
phenotype that affects around 50% of individuals with AD. We hypothesized that distinct
interactions between brain structures and genetic variants in dopaminergic, cholinergic and
glutamatergic neurotransmitter systems may be associated with the presence of hallucinations
and delusions in AD. Using the Alzheimer’s Disease Neuroimaging Initiative, we identified
participants that presented with symptoms of delusions, hallucinations, or both symptoms.
PLS-CA was used to identify differences in patterns of interactions between 15 single
nucleotide polymorphisms and 82 neuroanatomical regions of interest between AD patients
endorsing symptoms of delusions, hallucinations, and matched AD controls. Binary logistic
regression analysis was used to cross-validate identified neuroanatomical differences. Results
provide preliminary evidence that genetic variants in the glutamatergic system, along with
regional brain changes, may uniquely identify those with hallucinations. A trend towards
significance was also found which suggests that atrophy to the frontal lobe coupled with
preservation of temporal lobe structures may be associated with symptoms of delusions in
patients with AD. Overall, results provide evidence of a unique signature of neuroimaging
and genetic interactions which may be associated with the presence of different psychotic
symptoms in AD.
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cholinergic system, dopaminergic system, glutamatergic system, neurotransmitters, Magnetic
Resonance Imaging, Partial Least Squares Correspondence Analysis.
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Chapter 1
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Literature Review
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1.1 Alzheimer’s Disease
Alzheimer’s disease (AD) is a progressive neurodegenerative disease and is the most
common cause of dementia. It affects close to 560,000 individuals in Canada alone and
around 44 million people worldwide with the prevalence projected to double in the next
ten years 1,2. Importantly, the cognitive and functional deficits that arise from AD are
more advanced than typical age-related cognitive decline and may present many years
prior to an established clinical diagnosis of AD. With a growing aging population in
Canada and worldwide, AD is not only a pressing concern for individuals and care-givers,
but also represents a much larger public health issue. As such, research endeavors aiming
to identify and characterize the underlying biological substrates contributing to the
progression of AD and its associated symptoms are increasingly important as a starting
avenue for the development of therapeutic interventions.

1.1.1 Stages of Cognitive Impairment and Progression to Alzheimer’s
Disease
AD is associated with gradual cognitive decline, with the specific disease trajectory for
each individual being modulated by a combination of biological, social and psychological
factors. Initial indications of prodromal AD are often reported as subjective cognitive
decline (SCD) with patients endorsing symptoms of worsening cognitive function without
clear impairments on cognitive screening tests 3,4. As cognitive functions decline, patients
may progress to develop Mild Cognitive Impairment (MCI) – characterized by a mildmoderate degree of cognitive impairment with preserved activities of daily living. A
diagnosis of MCI is established through a comprehensive patient history and validated
cut-off scores on neuropsychological testing including the Mini Mental State Exam
(MMSE) 5 and the Montreal Cognitive Assessment (MoCA)6,7. An important distinction
to note, is that those with MCI can be categorized into two major subgroups – amnestic
MCI (aMCI) and non-amnestic MCI (naMCI), with the key distinguishing feature
between the latter and the former being the predominance of memory impairments 8.
aMCI is often referred to as MCI due to AD, given its increased risk of progression to
AD, with one study identifying an 8.5-fold increased risk for those with probable aMCI of
converting to dementia 9. This distinction has been further supported by structural
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neuroimaging studies which implicate a greater reduction in volume and cortical
thickness of key memory structures such as the hippocampus and the entorhinal cortex in
patients with aMCI when compared to naMCI and healthy older controls 10. Eventual
progression to AD is characterized by severe cognitive and functional impairments that
limit one’s ability to carry out activities of daily living. These symptoms include memory
loss, impaired reasoning and judgement, and changes in personality and behaviour –
likely attributable to advanced neurodegeneration that hinders the brain’s ability to
compensate for disruptions in regional cortical networks.
Early-Onset Alzheimer’s Disease (EOAD). About 5.5% of individuals diagnosed with
AD are affected by early-onset or familial AD 11. EOAD differs from late-onset
Alzheimer’s disease (LOAD) in that it affects individuals who are less than 65 years of
age. Individuals with EOAD with a family history of AD may present with genetic
mutations linked to three key genes – the Amyloid Precursor Protein 12, Presenilin 113,
and Presenilin 2 14. Mutations in these genes have been found to be associated with the
accumulation of beta-amyloid in the brain contributing to increased plaque pathology.
Late-Onset Alzheimer’s Disease (LOAD). LOAD is a term used to classify individuals
who develop AD after the age of 65. The greatest risk factor for LOAD is age, with the
risk of AD doubling every 5 years after the age of 60 15. In addition to age, other genetic
and environmental factors may also contribute to the development of LOAD. The major
genetic risk factor for LOAD is the apolipoprotein E (APOE) gene, a key gene in the
central and peripheral nervous system involved in lipid transport 16,17. In particular, when
compared to the more common E3/E3 genotype, those with one copy of the E4 allele
have a three-fold increased risk of AD, while those with two copies of the allele have an
8-12 fold increased risk 18,19. The mechanism by which the E4 allele is thought to
contribute to AD pathology is through the decreased ability to clear beta-amyloid, leading
to the aggregation of beta-amyloid into fibrils and plaques which subsequently contribute
to disruptions in synaptic connectivity and neurodegeneration in AD 20.The
immunoreactivity of ApoE has also been shown to be associated with amyloid deposits
and neurofibrillary tangles 21. Protective factors against AD include carrying the E2 allele
of the APOE gene, more years of formal education, physical activity, and social
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engagement 22–25. Both increased educational attainment and social activity are thought to
be protective against AD due to their proposed ability to increase cognitive reserve. In
this case, cognitive reserve refers to the brain’s ability to adapt to pathological changes
arising from AD, by using either compensatory strategies or other means of cognitive
appraisals. Overall, these observations suggest that increased cognitive reserve may make
individuals more resilient to early disruptions in normal cognitive functioning arising
from the pathology of AD, and delay the onset of identifiable cognitive impairment 26–28.

1.1.2 Neuropathology of Alzheimer’s disease.
The two cardinal pathological features of Alzheimer’s disease – beta-amyloid plaques and
neurofibrillary tau tangles (NFTs), were first identified and described by Alois
Alzheimer29,30. The aggregation of extracellular beta-amyloid, in particular the neurotoxic
Aß42 form of the protein, has been identified to lead to the formation of oligomers and
senile plaques throughout the brain in patients with AD 31,32. Beta-amyloid has also been
implicated in the amyloid cascade hypothesis which postulates that AD progression is
driven by the accumulation of insoluble extracellular beta-amyloid plaques. This
accumulation is thought to disrupt downstream processes and contribute to the abnormal
phosphorylation of tau proteins. Collectively, both the beta-amyloid and tau pathology
arising from this cascade is thought to lead to disruptions in synaptic connectivity and
ultimately neuronal death 33.
NFTs are abnormally phosphorylated tau proteins localized within neurons. The
accumulation of phosphorylated tau proteins leads to misfolding and disruption of
intraneuronal cytoskeletal architecture resulting in decreased cell stability 34–36. NFTs are
initially found regionally distributed in cortical and subcortical structures involved in
memory and cognitive function, with their presence in these regions corresponding with
early symptoms characteristic of AD. These include structures within the temporal lobe
such as the entorhinal cortex, hippocampus, amygdala and posterior parahippocampal
regions 37. Overtime, paralleling disease progression, NFTs become more dispersed and
affect structures involved in language, personality and motor coordination. Given the
positive correlation between NFT pathology and AD progression, clinical evaluations
characterize AD progression using NFT pathology as a severity and stage marker of AD
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. Taken together, both beta-amyloid plaques and NFTs are associated with disruptions in

normal cell-signaling which ultimately manifests biologically as localized cortical
atrophy in regions affected by these lesions, and behaviorally as impairments in memory,
language and other cognitive and non-cognitive domains.

1.1.3 Neuropsychiatric and behavioural symptoms in Alzheimer’s
disease
In addition to cognitive impairments, many patients with AD also develop non-cognitive
symptoms such as neuropsychiatric symptoms which are interchangeably referred to as
behavioural and psychological symptoms of dementia. The prevalence of these symptoms
in patients with dementia has been shown to be nearly universal with close to 97% of
patients developing at least one neuropsychiatric symptom 39. The comorbid presentation
of AD with neuropsychiatric symptoms has been shown to be associated with more rapid
cognitive decline, higher rates of institutionalization, and greater care-giver and financial
burden 40–42. In a clinical setting, the most widely used assessment for neuropsychiatric
symptoms in individuals with dementia is the Neuropsychiatric Inventory (NPI)43. The
NPI evaluates the frequency and severity of 12 neuropsychiatric symptoms including
delusions, hallucinations, agitation, dysphoria, anxiety, apathy, irritability, euphoria,
disinhibition, aberrant motor behaviour, night-time behaviour disturbances, and appetitive
and eating abnormalities. The NPI has also been adapted into a validated brief clinical
form known as the Neuropsychiatric Inventory Questionnaire (NPI-Q)44 which assesses
the presence or absence of these neuropsychiatric symptoms. A systematic review by
Zhao and colleagues (2016) found that in patients with AD, apathy was the most common
NPS with a prevalence of 49%, while euphoria was the least common with a prevalence
of 7%. Further studies have used techniques such as factor analysis to categorize these
symptoms into distinct subgroups including, 1) Hyperactivity (agitation, disinhibition,
irritability, and aberrant motor behaviours); 2) Psychosis (hallucinations, delusions, nighttime behaviour disturbance); 3) Affective (depression, anxiety); and 4) Apathy 45. Of
particular importance is that the psychosis subsyndrome was associated with the highest
overall NPI score, suggesting that the presence of these symptoms may further exacerbate
cognitive and functional decline in patients with AD.
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1.1.4 Primary Psychosis vs. Secondary Psychosis
Psychotic symptoms are common and characteristic phenomenon of primary psychotic
disorders such as schizophrenia but may also arise as presenting symptoms in other
diseases 46. When psychosis arises as a symptom of a pre-existing medical condition, for
example as a symptom of delirium 47, neurologic, or neurodegenerative disorder, this
presentation is referred to as secondary psychosis. A key distinguishing feature of
primary psychosis from secondary psychosis arising from AD, is that on cognitive
screening, those with primary psychosis retain the ability to remain oriented to the world
around them 48. When comparing the two most common psychotic symptoms – delusions
and hallucinations, in those with schizophrenia and AD, a few key differences are
important to note. Firstly, delusional symptoms in schizophrenia tend to be more complex
and bizarre, while in AD delusions tend to be simpler, with the most common being
paranoid delusions such as delusions of theft or infidelity 49,50. This distinction is
supported by neuroimaging studies which further suggest that delusions in AD may arise
as a result of progressive memory and cognitive impairments 51,52, which in turn may
generate states of confusion or paranoia ultimately leading to delusional symptoms 53.
Secondly, individuals with schizophrenia also predominantly experience auditory
hallucinations but may also experience hallucinations in other sensory modalities. The
hallucinations experienced by those with schizophrenia are typically described as
Schneider’s first-rank symptoms indicating a loss of self vs. non-self distinction (e.g.
hearing third-person voices talking to one another about oneself, intrusive second-person
voices commenting on an individual’s thoughts and behaviours)54. In contrast, visual
hallucinations tend to be more common in individuals with AD and include seeing
people or animals 55. While the presentation of psychotic symptoms may vary in those
with schizophrenia and AD, neuroimaging studies have implicated similar brain regions
suggesting an overlapping neuropathology, discussed in further detail below, which may
contribute to the development of hallucinations and delusions in these disorders.

1.2 Psychosis and Alzheimer’s disease
The co-occurrence of psychotic symptoms and AD is a devastating phenotype (AD+P)
that affects close to 40% of individuals with AD 41, making it one of the most common
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psychotic disorders – second only to schizophrenia 49,56. When describing psychotic
symptoms in AD, the two most common symptoms that fall under this category are
delusions and hallucinations. Delusions are defined as persistent false beliefs that are
resistant to reasoning and are independent of any cultural beliefs. Hallucinations are
defined as sensory perceptions, of any sensory modality, that occur in the absence of any
external stimuli. Notably, in AD, the presence of these symptoms begins early in the
disease course and remains persistent over time. For example, a study by Paulsen and
colleagues (2000)57, showed that in a sample of 329 AD patients, 20% had symptoms of
hallucinations or delusions at baseline, with the cumulative incidence increasing to
around 51% at four years follow-up. When compared to other neuropsychiatric symptoms
in AD, such as agitation, aggression or disinhibition, the grouping of hallucinations and
delusions into one overarching category in many factor analytic and latent class analysis
studies, suggests that these symptoms may have some shared neural correlates 45,58,59. But
when broken down further, more recent studies suggest a divergence in psychotic
symptomatology and consequently raise the question of whether the final pathway that
leads to the presentation of hallucinations and delusions in AD may differ 60,61. Studies
that have subdivided psychotic symptoms to identify the individual prevalence of
delusions and hallucinations have consistently found that delusions tend to be more
common in those with AD when compared to hallucinations 62,63. In a systematic review,
the prevalence of delusions was found to range from 9 – 59% in individuals with AD,
with a pooled-prevalence of approximately 31%, while the prevalence of hallucinations
was found to range from 6 – 41%, with a pooled prevalence of approximately 16% 64.
Given that delusions and hallucinations may be associated with distinct biological
correlates, developing a better understanding of how they uniquely arise may provide
greater insight into more specific and targeted treatment options for each symptom.

1.2.1 Delusions in Alzheimer’s disease: Cognitive models and
neuroanatomical correlates
Investigations into the neuroanatomical and pathological correlates of delusions in AD
have led to the proposition of three key theories that may explain the etiology of
delusions in AD 65. The first model is known as the hypofrontality model which
postulates that delusions in AD arise as a result of disrupted frontal lobe function either
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due to atrophy to frontal brain regions or hypoperfusion in these areas. Evidence in
support of this model include neuroimaging studies using single photon emission
computed tomography (SPECT) and positron emission tomography (PET) which suggest
that individuals with AD and delusions (AD+D), when compared to controls, have
hypoperfusion in frontal brain regions 66–68. A limitation of this theory is that it
presupposes that all delusional symptoms may arise as a result of frontal pathology
without acknowledging that different types of delusions for example, misidentification
and paranoid delusions may have additional unique neural substrates. For example, an
earlier PET study of AD patients with misidentification delusions, found that patients
with these delusions compared to AD controls, had more pronounced bilateral cingulate
and basal ganglia hypometabolism, in particular in regions of the orbitofrontal, middle
temporal, anterior and posterior cingulate, left caudate nucleus, left lentiform nucleus, and
the left calcarine69. Results of this study suggest that it may not just be the frontal lobes
that are implicated in AD+D, but rather coordinated networks of regions which may
contribute to the presence of specific types of delusions in AD. In particular, given the
involvement of the basal ganglia, there may be limbic loops extending from subcortical
structures to frontal regions of the cortex which may explain the distressing emotional
aspects of delusional symptoms.
The second theory proposes that delusions may be non-cognitive manifestations of AD
and are based on research findings that suggest that individuals with AD+D may have
greater behavioural impairments independent of AD neuropathology when compared to
those without delusions 70,71. More specifically, this theory proposes that individuals with
AD+D do not significantly differ in cognitive abilities on neuropsychological testing
when compared to individuals without delusions, but that they do have more severe
behavioural symptoms such as aggression and other activity disturbances. As such,
according to this theory, scores on neuropsychological testing alone would not be
predictive of the subsequent development of delusions in AD. From a neuropathological
level, Sweet and colleagues (2000)71 found that AD+P was not associated with increased
severity of plaque and tangle formation when the sample was controlled for the presence
of Lewy bodies. A few limitations of this theory include the lack of consideration that
perhaps aggressive behaviours may make individuals more prone to psychosis or vice
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versa. Namely, those with symptoms of aggression may be more inclined to exhibit
paranoid delusions in which they believe that others are stealing from them or fear
persecution from those around them. Contrarily, delusional belief that others are out to
get them, may actually perpetuate aggressive behaviours. As such, it would be important
to dissociate whether delusions exhibited by those with other behavioural symptoms are
in fact organic delusions or whether they occur in response to, or a result of, aggressive
behaviours and can be resolved upon treatment of aggressive symptoms.
In contrast, the third theory proposes that AD+D may arise as a result of the
pathophysiology of AD. With respect to this theory, the pathophysiology of AD is
defined in reference to the characteristic features of AD – namely amyloid plaques and
neurofibrillary tangles. Unlike the aforementioned theory, this model proposes that the
increased severity of these plaques and tangles may contribute to the presence of
delusions in AD. In support of this model, studies have found independent associations of
psychotic symptoms with neurofibrillary tangle density 72 and senile plaques 73. These
differences in findings when compared to the previously described theory could be
attributed to the lack of control for those with Lewy body dementia (LBD), as well as
different methodological approaches with regards to specific brain regions that were
investigated.
While these theories have been used to describe the biological correlates of delusions
more generally, it is important to note that delusions in AD can be categorized into two
major subgroups – paranoid and misidentification delusions 74. Paranoid delusions
include delusions of persecution, theft, as well as infidelity. Misidentification delusions
include Capgras syndrome in which an individual believes someone close to them has
been replaced by an imposter; TV sign, in which they believe that characters or situations
depicted on TV shows are real; and phantom boarder syndrome in which they believe that
a stranger is inhabiting their house. In contrast to the theories proposed above, a review of
more recent studies suggest that paranoid and misidentification delusions may have
distinct neuropathological correlates, with paranoid delusions being associated with more
frontal impairments and misidentification delusions with medial temporal lobe structures
75

.
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In addition to these three theories, many studies also suggest a hemispheric lateralization
for delusions, with the majority of studies implicating right hemisphere dysfunction
57,67,76

. In particular, it has been hypothesized that atrophy in the right hemisphere may

lead to changes in memory, thinking, reality monitoring failure, and impairments in
autobiographical memory retrieval, which in turn may manifest as delusional judgements
or beliefs that can be communicated if there is relative preservation of the left hemisphere
77,78

. Collectively, these theories suggest that there may be multiple factors contributing

to the pathology of AD+D, with the majority suggesting involvement of the frontal lobes
as being the driving factor behind delusional beliefs.

1.2.2 Hallucinations in Alzheimer’s disease: Cognitive models and
neuroanatomical correlates
Hallucinations in Alzheimer’s disease (AD+H) can be associated with any sensory
modality but the two most common types of hallucinations in AD tend to be visual and
auditory 79–81. Understanding the underlying biological correlates of hallucinatory
symptoms is increasingly important since previous research suggests that the presence of
hallucinations in AD is associated with more rapid cognitive deterioration and an
increased risk of mortality 82–84. With regards to the neuroanatomical correlates of
hallucinations, some studies suggest the involvement of corresponding sensory brain
regions with particular modalities of hallucinations (i.e. primary auditory cortex in
auditory hallucinations, visual cortex for visual hallucinations) and go further to suggest
that specific brain regions may be linked to the content of hallucinations 85. Being able to
correlate hallucinations with specific brain regions is particularly important because it
may suggest that localized pathological abnormalities are associated with subtypes of
hallucinations and therefore help to guide more targeted treatment options.
When looking at the neuroanatomical correlates of hallucinations in AD specifically,
there have been conflicting hypotheses as to what may generate these symptoms. Some
studies suggest that visual hallucinations may arise as a result of occipital lobe atrophy 86,
while others suggest that relative preservation of the cortex is necessary to generate
psychotic symptoms in AD 87. In support of the posterior atrophy and hypometabolism
model, one study found that subcortical white matter lesions in occipital regions –
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hypothesized to be an indication of abnormalities in the primary visual pathway, were
associated with AD+H in the absence of any visual acuity deficits 88. Controlling for
visual acuity is particularly important in an elderly population, given that other neurologic
deficits, such as Charles Bonnet syndrome may also give rise to hallucinations 89. Charles
Bonnet syndrome is also characterized by symptoms of visual hallucinations but in this
case these symptoms arise as a result of vision loss from eye conditions such as macular
degeneration. In addition to the neuroanatomical correlates of hallucinations, one study
also suggests that hallucinations in AD are associated with a decline in inhibitory control
and difficulty in suppressing intrusive memories or thoughts which may then be
misattributed to external stimuli 90. Overall, given the heterogeneity of hallucinations,
there is no clear consensus in the field as to what may be the underlying mechanism of
hallucinations in AD, but the existing literature does suggest that brain regions involved
in different sensory process may be associated with hallucinations of the same modality.

1.3 Genetic Correlates of Psychosis
While there is significant evidence that regional brain atrophy may contribute to the
formation of hallucinations and delusions, what remains unclear is why a proportion of
individuals with AD develop psychotic symptoms while others remain asymptomatic
throughout their disease course. To address this variability, some studies have looked into
the heritability of AD+P and have found evidence of a familial aggregation of AD+P
60,91,92

. These studies have also identified a heritable component, with one study

estimating the heritability of LOAD and psychotic symptoms to be around 61% 93.
Collectively, these studies provide strong evidence in support of a genetic component to
AD+P and highlight the importance of understanding the genetic factors which may
contribute to the development of psychotic symptoms in AD. Genetic variants in
neurotransmitter pathways are of particular interest, given the modulation of psychotic
symptoms by treatments that target neurotransmitters in several neuropsychiatric
disorders. More specifically, studies that have examined neurotransmitters involved in the
development of schizophrenia as well as other neurodegenerative diseases that present
with psychiatric symptoms, such as AD, have implicated a role of the cholinergic,
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dopaminergic and glutamatergic neurotransmitter system in the development of delusions
and hallucinations.

1.3.1 Cholinergic System
One of the pathologies of Alzheimer’s disease is the loss of neurons in the Nucleus
Basalis of Meynert, a major source of cholinergic innervation to the cerebral
cortex94,95.The neurotransmitter acetylcholine (ACh) plays an important role in memory,
arousal and learning. Consequently, the cholinergic deficiencies which arise in AD have
led to the development of the cholinergic hypothesis in explaining the cognitive and
behavioural changes, including neuropsychiatric symptoms, in AD 96,97. The cholinergic
hypothesis of neuropsychiatric symptoms in AD proposes that the projections from the
nucleus basalis, which enables limbic-neocortical interactions, becomes disrupted and
consequently alters emotional and motivational states, leading to the observed
behavioural changes in AD 98. Recent genome-wide analysis studies (GWAS) have begun
to investigate single nucleotide polymorphisms (SNPs) in neurotransmitter systems to
identify if certain polymorphisms may be risk factors for the development of psychosis in
AD 99. For example, a significant association between the development of delusions and a
polymorphism (rs6494223) in the alpha-7 nicotinic acetylcholine receptor gene has been
identified 100. Moreover, patients treated with donepezil, a cholinesterase inhibitor, have
shown improvements in delusional symptoms suggesting that imbalances in the
cholinergic system, in particular within frontal brain regions, may be associated with the
emergence of delusional symptoms in AD101.

1.3.2 Dopaminergic System
The dopamine system has been extensively studied in relation to the positive and negative
symptoms of schizophrenia. More specially, the dopaminergic hypothesis postulates that
the positive symptoms of schizophrenia (i.e. hallucinations, delusions etc.) may arise as a
result of increased dopamine levels in the striatum, stemming from increased D2/D3
receptor density 102,103. Given the findings that symptoms of psychosis may arise as a
result of dopamine irregularities, studies have likewise examined the effect of dopamine
specific polymorphisms and the development of psychotic symptoms in
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neurodegenerative diseases. One such study by Sweet and colleagues (1998)104, found
that polymorphisms in the dopamine D1 and D3 receptor conferred a moderate risk of
developing psychotic symptoms in AD. Similarly, a polymorphism in the catechol-Omethyltransferase (COMT) gene, which leads to the upregulation of striatal dopamine,
has been shown to be a risk factor for the development of psychosis in AD 105.

1.3.3 Glutamatergic System
The glutamate system is likewise an appropriate candidate system to assess in relation
with psychotic symptoms given that abnormal glutamate activity in schizophrenia is
hypothesized to contribute to the development of hallucinations and delusions. Studies
such as those conducted by Mogahaddam et al., (1997)106 and Bickel and Javitt (2009)107,
provide support that antagonism of NMDA receptors elevates extracellular glutamate
levels which may in turn lead to the development of psychotic symptoms similar to those
seen in schizophrenia. On the other hand, excessive NMDA activity is associated with
neurotoxicity which can lead to neuronal cell death, as can been seen in many
neurodegenerative diseases such as AD 108. To further support the role of the glutamate
system in the development of psychotic symptoms, Begni and colleagues (2003)109, found
that the G1001C polymorphism in the Glutamate Ionotropic Receptor NMDA Type
Subunit 1, in particular the C allele, was significantly associated with an increased risk of
Schizophrenia (OR = 2.04). Through examining the functional effects of the G1001C
polymorphism, the authors identified that this polymorphism may exert its biological
effects by altering the consensus sequence in the nuclear factor kappa-light-chain
enhancer of activated B-cells (NF-kB) transcription factor, a protein complex involved in
DNA transcription. As such, investigating polymorphisms in the glutamate system may
provide additional information on how psychotic symptoms may arise in AD.

1.3.4 Current Treatment Approaches
Current treatment approaches for psychotic symptoms in AD include the use of atypical
antipsychotics such as risperidone, olanzapine, and aripiprazole but have been associated
with limited efficacy and severe side effects in patients with dementia, deriving from a
lack of biological specificity. A review of 16 placebo-controlled trials suggests that the

14

use of risperidone may modestly improve psychotic symptoms in AD but is also
associated with severe adverse outcomes including cerebrovascular and extrapyramidal
side effects. Given the modest efficacy and vast side-effect profile, it was concluded that
risperidone should not be used to routinely treat patients with AD+P 110. A subsequent
review identified that those with more severe symptoms of AD+P were those that may
benefit the most from risperidone treatment 111. Aside from risperidone, a clinical trial of
aripiprazole in patients with a definitive diagnosis of AD+P, showed only a modest
benefit when compared to placebo in improving psychotic symptoms. One identified
benefit of aripiprazole when compared to other atypical antipsychotics, was that it was
associated with minimal adverse side effects in patients with AD, although it did have
minor negative effects on cognition 112. However, it is also important to note that a review
looking at the mortality rates associated with general atypical antipsychotic use found that
there was an increased risk of mortality in patients with dementia that used these drugs
(OR: 1.54)113. These findings of adverse and limited side-effects associated with current
treatments for psychosis in AD, reiterate the importance of identifying more specific
treatment options that target psychotic symptoms in AD. This is particularly important
given that earlier interventions may improve the quality of life of those with AD+P,
reduce long-term health care costs, and reduce the risk of institutionalization.

1.4 Neuroimaging and Genomics
Previous research has examined whether regional brain changes or genetic
polymorphisms in neurotransmitter systems may give rise to psychotic symptoms.
However, the results to date have been inconsistent because of a lack of dissociation of
psychosis into the different subtypes. In addition, few studies have linked brain imaging
and genetics together to investigate how the interaction between these two factors may
mediate the presence of hallucinations and delusions in AD specifically. A previous study
using neuroimaging genomics (the integration of neuroimaging and genetic techniques)
and machine learning to predict AD, showed that adding genetics (in particular SNPs) to
other imaging modalities may help improve the classification accuracy of AD 114. One
other study used large scale brain mapping for gene discovery to look specifically for
SNPs that may be associated with temporal lobe volume. This study found that the risk
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allele for rs10845840 located in the GRIN2B gene was associated with lower temporal
lobe volume and overrepresented in AD/MCI subjects when compared to controls 115.
Although these studies did not look at particular symptoms of AD, these findings suggest
that considering the interaction between neuroimaging and genetic factors may provide
additional valuable information to aid in classification of participants. This is particularly
important for psychotic symptoms in AD, given that hallucinations and delusions may
arise as a result of imbalances in different neurotransmitter systems which may become
more pronounced as a result of regional brain changes arising from AD.

1.5 Rationale and Hypothesis
The purpose of this study was to investigate the relationship between regional brain
changes and genetic polymorphisms in neurotransmitter systems and the presence of
hallucinations and delusions in AD. Given prior findings that there may be anatomical
variations in individuals with AD, we sought to investigate whether these differences may
indicate different phenotypes of AD. In particular, with regards to psychotic symptoms in
AD, studies suggest that the frequency of these symptoms may vary across individuals
with AD, with some individuals developing psychosis and others remaining
asymptomatic throughout their disease course. Furthermore, there remains limited
evidence and consensus in the literature with regards to particular brain regions that may
be associated with symptoms of hallucinations and delusions. As such, we hypothesized
that the interactions between regional brain structures and genetic variants in cholinergic,
dopaminergic or glutamatergic neurotransmitter systems would be associated with
symptoms of psychosis in AD, and that the distinct nature of these interactions would
differ for those with delusions when compared to those with hallucinations. More
specifically, we rationalized that investigating the interactions between regional brain
changes and genetic variants would be critical in identifying whether the functional
effects of specific genetic polymorphisms are unmasked as a result of regional brain
changes arising from AD. We predicted that delusions and hallucinations are
predominantly caused by the interaction of right frontal brain changes and genetic
polymorphisms in dopaminergic, cholinergic, or glutamatergic neurotransmitter systems.

16

Chapter 2

2

Methods

17

2.1 ADNI Overview
Data used in the preparation of this article was obtained from the Alzheimer’s Disease
Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). The ADNI was launched in
2003 as a public-private partnership, led by Principal Investigator Michael W. Weiner,
MD. The primary goal of ADNI has been to test whether serial magnetic resonance
imaging (MRI), positron emission tomography (PET), other biological markers, and
clinical and neuropsychological assessments can be combined to measure the progression
of mild cognitive impairment (MCI) and early Alzheimer’s disease (AD). All subjects in
ADNI undergo both cognitive and clinical assessments and have structural MRIs taken
for 2-3 years at pre-scheduled intervals. AD patients undergo a baseline assessment and
then an assessment at, 6, 12 and 24 months. MCI patients at high risk for conversion to
AD undergo a baseline assessment and then subsequent assessments at 6, 12, 18, 24 and
36 months. Participants from earlier ADNI cohorts were also followed in ADNI2/GO and
ADNI3 where they were assessed at baseline enrollment, month 3, month 6, month 12,
and annually thereafter. For up-to-date information, see www.adni-info.org.

2.2 Participants
Subjects were selected from the ADNI database and categorized into distinct subgroups
based on endorsed symptoms of psychosis as assessed by the Neuropsychiatric Inventory
(NPI)43 or Neuropsychiatric Inventory questionnaire (NPI-Q)44. Inclusion criteria for
patients endorsing psychotic symptoms included a clinical diagnosis of AD or MCI due to
AD, at least one episode of delusions or hallucinations as assessed by either the NPI or
NPI-Q delusion and/or hallucination domain scores, an available UCSF volumetric
measurement of a 1.5T or 3T MRI scan at or after the first onset of psychosis
(delusions/hallucinations), and genome wide analysis data. Inclusion criteria for control
participants included a clinical diagnosis of AD, the absence of delusions and
hallucinations throughout the course of the ADNI studies, at least three available UCSF
volumetric measurement of a 1.5T or 3T MRI scan, and available genome wide analysis
data, as of ADNI data available on January 1, 2018. Exclusion criteria for both groups
included a history of brain injury, other neurological disorders (ex. Dementia with Lewy
Bodies, Parkinson’s disease etc.), psychiatric disorders (ex. Schizophrenia, Bipolar
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disorder etc.) or strokes, as determined based on clinical assessment, which could account
for the presence of delusions and/or hallucinations.
All participants who developed psychotic symptoms were matched as closely as possible
with AD patients that did not develop that particular symptom (i.e. hallucinations or
delusions) for disease severity using the scores from the Clinical Dementia Rating scale
(CDR) global score, sex, age, cognitive ability using the Mini Mental State Exam
(MMSE) total score, years of education, number of ApoE4 alleles, and MRI scanner
strength. To match the group of participants endorsing symptoms of psychosis with the
control group, the range of values of age, education, CDR global score, and MMSE total
score for those endorsing symptoms of delusions and/or hallucinations were applied as a
filter to the available control group.

2.3 Demographic and Behavioural Data Analysis
Delusion and hallucination domain scores from the Neuropsychiatric Inventory
Questionnaire (NPI-Q) and the full Neuropsychiatric Inventory (NPI) were extracted from
the ADNI database for participants meeting the inclusion criteria as defined above on
January 1, 2018. Phase 1 of ADNI (ADNI-1) used the NPI-Q which provides a binary
response (yes or no) to assess the presence or absence of symptoms for each domain.
Phase 2 of ADNI (ADNI-GO/2) used the full NPI which allows for the identification of
specific subtypes of neuropsychiatric symptoms. Prompts for the delusion domain on the
NPI include paranoid ideations such as believing that their life is in danger or that others
are stealing from them, and misidentification phenomenon such as believing that their
spouse is not who they claim to be. Prompts for the hallucination domain on the NPI
include endorsement of abnormal visual, auditory, olfactory, or tactile sensations and/or
perceptions in the absence of any external stimuli; for example, hearing voices or seeing
things that are not actually present. For participants endorsing psychotic symptoms on
multiple visits, data from the first ADNI visit in which psychotic symptoms
(delusions/hallucinations) were present were included in the analysis. For the control
group, the NPI and NPI-Q scores for all available ADNI visits were reviewed to ensure
that participants did not develop delusions and/or hallucinations over their disease course.
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2.4 Neuroimaging Data Preprocessing and FreeSurfer
Analysis
High resolution anatomical T1weighted images were preprocessed by the Mayo Clinic.
Initial preprocessing included a two-step quality assessment procedure. The first step
involved assessing adherence to defined ADNI MRI collection protocol. The second
preprocessing step involved series-specific quality assessment and included gradient
warping, scaling, and correction for image intensity and inhomogenities. Preprocessed
ADNI cross-sectional data [UCSFFSX] images were then analyzed by the UCSF ADNI
group (Co-I Norbert Schuff) using FreeSurfer version 4.3 for images collected at 1.5T
and FreeSurfer version 5.1 for images collected at 3T. Although two different fieldstrengths were used, FreeSurfer procedures have been shown to have good re-test
reliability across field strengths116,117. The T1 weighted images were processed and
segmented using the 2010 Deskian-Killany atlas and the 2009 Destrieux atlas. Briefly, the
processing steps included segmentation of grey matter, white matter and subcortical
structures and subsequent cortical parcellation. A visual quality control was performed to
assess overall segmentation accuracy118–129. It is important to note that cortical thickness
estimates have been shown to vary across different versions of FreeSurfer130, but it has
also been shown that within the ADNI cohorts, FreeSurfer version does not affect the
reliability of patient classification on diagnostic group (healthy controls, MCI or AD)
based on cortical thickness measurements obtained from FreeSurfer131.
In order to conduct a whole brain analysis, eighty-two cortical and subcortical regions of
interest (ROI) from the UCSF FreeSurfer cross-sectional ADNI data analysis were
included (Appendix A). Cortical thickness and subcortical volume measurements for the
ROIs were extracted. To account for individual variations in brain size, all subcortical
volume measurements were adjusted for total intracranial volume (TIV). This was done
since prior literature suggests that volume but not cortical thickness measurements are
highly correlated with TIV 132–134. MRI data was only included if it passed or partially
passed regional image segmentation quality assessment of the frontal, temporal, occipital
and basal ganglia regions. For subsequent statistical analyses, volume and cortical
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thickness measurements were adjusted for sex, age, years of education, CDR global score,
MMSE total scores, either through regression models or by including these variables as
covariates. All cortical and subcortical measurements were also transformed into z-scores
before further analyses.

2.5 Genetic Data Acquisition and Preprocessing
DNA information was derived from one of two sources: 1) peripheral blood, or 2)
immortalized lymphocyte cell lines. ADNI-1 participants were genotyped using the
Illumina Human610-Quad BeadChip (Illumina, Inc. San Diego, CA). All genotyping and
initial preprocessing was conducted by the ADNI Genetics Core group. Further details on
genotyping methods and preprocessing have been outlined by the ADNI Genetics Core
group 135. Initial quality control (QC) and imputation was performed by Sejal Patel and
the lab of Dr. Jo Knight at the University of Toronto. Genotype imputation is a procedure
whereby unsequenced SNPs are inferred based on directly sequenced SNPs. This
procedure works on the premise that groups of SNPs are likely to be inherited together
(haplotypes). SNPs that have been sequenced act as markers which are then compared to
the haplotypes of individuals in a reference panel (ex. HapMap). Regions of shared
genotypes between the sequenced individuals and the reference panel are then identified.
The reference panel is then used to infer unsequenced genotypes for SNPs that were not
directly sequenced136.
QC was performed on the ADNI1 GWAS data (N=757) using PLINK (version 1.07,
Purcell et al., 2007). Individuals with discordant sex information (when samples are
incorrectly marked as male or female based on ascertained sex), high level of missing
data (> 2%) and heterozygosity rates greater than three standard deviations from the mean
were removed from the sample. One of each pair of individuals displaying a high level of
pair-wise identity by descent (IBD > 0.185) were also removed. In addition, SNPs with
minor allele frequency (MAF) <1% and Hardy-Weinberg equilibrium (p < 1x10-7) were
removed. After QC, 662 individuals remained in the analysis set. Multidimensional
scaling (MDS) was performed in PLINK using HapMap3138 as a reference panel. When
the population was compared with the CEU (CEPH - Utah residents with ancestry from
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northern and western Europe), YRI (Yoruba in Ibadan, Nigeria), JPT (Japanese in Tokyo,
Japan), TSI (Tuscans in Italy) and CHB (Han Chinese in Beijing, China) ancestry, the
sample clustered around CEU and TSI sample. MDS was subsequently carried out with
the ADNI1, CEU, TSI and Jewish ancestry samples and aligned completely with the later
three samples. The ADNI1 dataset was imputed using 1000 Genomes Phase I integrated
variant set (March 2012). Given the small sample size of participants that were of nonHispanic Caucasian ethnicity, these individuals were removed prior to subsequent
analysis to control for any confounding effects. From the preprocessed data, we then
selected only participants meeting the inclusion criteria defined above.

2.6 Candidate SNP Selection
After conducting a thorough review of the literature, we identified SNPs with known
functional consequences and associations with neuropsychiatric symptoms, focusing in
particular on SNPs in the following genes in the cholinergic system: BCHE, ACHE,
CHRNA7, CHRNA4, CHRNB2; and in the following genes in the dopaminergic system:
COMT, DRD1, DRD2, DRD3; and in the glutamatergic system: GRIN1, GRIN2A,
GRIN2B, GRIN2C, GRIN2D, GRIN3A. Concluding our review, we selected 15
candidate SNPs to include (Table 1,2). Given that there is limited literature on SNPs in
neurotransmitter systems that may be associated with psychosis in AD, the SNPs that we
selected have previously been reported to be implicated in the development of psychotic
symptoms in other neurodegenerative or psychiatric disorders, associated with AD, and/or
to have functional consequences on transcript or protein levels. SNP data were recoded
into disjunctive format prior to additional analyses. Using this format, each SNP was
treated as a categorical variable with three levels (i.e. homozygous dominant,
heterozygous, homozygous recessive). The advantages of coding SNPs using this
genotypic model have been outlined previously in Beaton, Dunlop, & Abdi (2015)139, and
include being able to assess the contribution of different alleles and genotypes to
observed phenotypic traits or behaviours. This is particularly important because the minor
or major allele coding scheme is often subjective and based on a particular cohort of
participants. As such, what is coded as the major or minor allele in one study may vary
across studies with different samples of participants. Using the genotypic model therefore
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allows us to treat each genotype as a categorical variable and investigate the unique
contribution of each genotype using a more general approach. To ensure that we were
sufficiently powered to assess the effects of different alleles/genotypes, homozygous
recessive genotypes with frequencies < 5%, were combined with heterozygous genotypes
to form one category (?a). This second grouping encompassed individuals with both the
homozygous recessive genotype (aa) and the heterozygous genotype (Aa).
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Table 1. Candidate single nucleotide polymorphisms (SNPs) in the Cholinergic (BCHE,
CHRNA7) and the Dopaminergic (COMT, DRD1, DRD2, DRD3) neurotransmitter
systems.
Gene

Chromosome

SNP

Literature Summary

Key Findings
•

Butyrylcholinesterase
(BCHE)

3

rs1803274

Darvesh, Hopkins &
Geula., (2003)140
Yoo et al., (2014)141

Cholinergic Receptor,
Nicotinic Alpha 7
Subunit

•

15

rs6494223

•

Frequency of delusional
symptoms was higher in
patients homozygous for the T
allele compared to the CC or
CT genotypes

•

Val carriers have high enzyme
activity, may have reduced
dopamine levels in the
prefrontal cortex, leading to
decrease in D1 receptors
activation
Can lead to impairment in
working memory
G allele of rs686 decreases the
levels of DRD1 expression by
inhibiting the binding of
microRNA miR-504 to the
DRD1 3′-UTR
Reported 50% of the time,
957C>T, decreased DRD2
mRNA stability and translation
and reduced dopamineinduced-up-regulation of
DRD2 membrane expression in
vitro
Alters the folding of the
mRNA, mRNA is less stable
which leads to markedly
reduced protein synthesis rates
Intronic SNP rs1076560
strongly associated with D2
short isoform/D2 long isoform
ratios with GG schizophrenia
subjects showing a higher
percentage of the D2 short

Carson et al., (2008)100

(CHRNA7)

Catechol-OMethyltransferase

22

rs4680

Rosa et al., (2004)142

(COMT)
•
•
Dopamine Receptor D1
(DRD1)

5

rs686

Huang et al., (2008)143

•

Dopamine Receptor D2
(DRD2)

11

rs6277

Duan et al., (2003)144
•

•
Dopamine Receptor D2
(DRD2)

11

rs1076560

Bertolino et al.,
(2009)145

BCHE – K variant has reduced
catalytic activity, about 30% of
the usual BChE
BCHE-K protects against
pathology of AD that affects
frontal cortical thickness and
neuropsychiatric symptoms
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•
Dopamine Receptor D2
(DRD2)

11

rs1800497

Makoff et al., (2000)146

•
Dopamine Receptor D3
(DRD3)

3

rs6280

Savitz et al., (2013)147

•

isoform mRNA in prefrontal
cortex than GT subjects
C allele is a risk factor for
hallucinations. This finding
was found to be clinically
significant in context of
advanced neurodegeneration of
chronic PD
Only known polymorphism that
alters protein structure in this
gene
Glycine allele yields D3
autoreceptors that have a higher
affinity for DA and display
more robust intracellular
signaling
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Table 2. Candidate single nucleotide polymorphisms (SNPs) in the Glutamatergic
(GRIN2A, GRIN2B, GRIN3A, GRIN3B) neurotransmitter system.
Gene

Chromosome

SNP

Glutamate Ionotropic
Receptor NMDA Type
Subunit 2A (GRIN2A)

16

rs9922678

Literature
Summary
Schizophrenia
Working Group.,
(2014)148

Key Findings

•
•

Glutamate Ionotropic
Receptor NMDA Type
Subunit 2B (GRIN2B)

12

rs1805502

Weickert et al.,
(2013)149

•

•
Glutamate Ionotropic
Receptor NMDA Type
Subunit 2B (GRIN2B)
Glutamate Ionotropic
Receptor NMDA Type
Subunit 2B
(GRIN2B)
Glutamate Ionotropic
Receptor NMDA Type
Subunit 3A
(GRIN3A)

12

rs1806201

Andreoli et al.,
(2014)150
•

12

rs10845840

Stein et al., (2010)115
•

9

rs3739722

Liu et al., (2009)151
•

Glutamate Ionotropic
Receptor NMDA Type
Subunit 3A
(GRIN3A)

9

rs10989591

Gallinat et al.,
(2007)152

Glutamate Ionotropic
Receptor NMDA Type
Subunit 3B
(GRIN3B/ABCA7 -in
linkage disequilibrium
with GRIN3B)

19

rs3764650

Karch et al.,
(2012)153

•

Minor homozygote associated
with the development of
schizophrenia (OR=1.06)
NR1 and NR2C mRNA
decreased in post-mortem brain
analysis of those with
schizophrenia
Found that the expression of
NR1 subunit mRNA was
significantly reduced in patients
with schizophrenia who were C
carriers of the SNP rs1805502
when compared to heterozygous
controls
(p =.008)
Significant contribution from the
GRIN2B rs1806201 T allele
towards Alzheimer’s disease
susceptibility (adjusted odds ratio
(OR=1.92, (95%CI: 1.40–2.63))
Risk alleles for lower temporal
lobe volume at this SNP were
significantly over-represented in
AD and MCI subjects versus
controls (OR=1.27; p =.039)
Genetic variation of the NR3A,
but not NR3B, subunit of the
NMDA receptor may be a risk
factor for AD pathogenesis
among the Taiwanese population
T,T individuals appeared to show
better prefrontal information
processing (higher frontal P300
amplitudes), could reflect higher
NMDA receptor efficacy
Minor allele associated with a
later age of AD onset and shorter
disease course
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2.7 Statistical Analysis
Independent samples t-tests were used to compare age, years of education, MMSE total
score and CDR global score for participants endorsing psychotic symptoms of interest
and control groups. For the comparison of multiple cohorts of participants with psychotic
symptoms, a Kruskal-Wallis test was used to determine group differences. Chi-square
tests were used to compare the two groups on sex distribution, number of ApoE4 alleles,
and scanner strength (1.5T vs. 3T).

2.7.1 Partial Least Squares Correspondence Analysis: Overview
Partial least squares correspondence analysis (PLS-CA) is a multivariate analysis
technique that is both a generalization of partial-least squares correlation (used in
neuroimaging studies) and an extension of correspondence analysis (dimension reduction
technique for categorical variables). This method was formalized by Beaton and
colleagues and is extensively detailed in their paper 139. To summarize, unlike traditional
PLS, PLS-CA is able to simultaneously analyze two data sets that contain both
continuous (i.e. neuroimaging) and categorical (i.e. genetic) variables. This process works
through transforming continuous variables, like cortical thickness and subcortical volume
measurements, into pseudo-categorical variables using an Escofier transformation. PLSCA uses generalized singular value decomposition to identify orthogonal pairs of
underlying latent variables, with the first extracted pair explaining the greatest amount of
covariance in the data sets. Non-parametric inferencing methods such as permutation and
bootstrap resampling techniques are used to identify significant and stable components.
With bootstrap confidence intervals, in particular, allowing for the post-hoc identification
of group level differences. In addition, through the use of PLS-CA, we are able to treat
SNPs as categorical variables, instead of as numeric based on the frequency of either the
minor or major allele, thereby allowing us to examine how different SNP genotypes
contribute to different effects within our sample. Overall, the PLS-CA approach can be
used to identify global level interactions. These interactions can be inferred based on the
latent factor and variable plots for each component. More specifically, ROIs and
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genotypes that are in the same direction as one another, on the same component, can be
inferred to be interacting together.

2.7.2 PLS-CA
Three independent PLS-CA were conducted to identify neuroanatomical and genetic
correlates of delusions and hallucinations. The rationale behind separating the analyses
into three different parts was to more closely examine the neuroanatomical and genetic
interactions with increased power resulting from a larger sample size. This was achieved
by first using a binary categorization scheme to identify interactions associated with the
presence vs. absence of delusions and subsequently the neuroanatomical and genetic
interactions associated with the presence vs. absence of hallucinations. The final analysis,
which combined both of the aforementioned cohorts, was conducted to identify and parse
any differences in neuroanatomical and genetic interactions for those with symptoms of
hallucinations, delusions or both. 82 ROIs and 15 SNPs were included in the analysis. All
cortical thickness and subcortical volume measurements were adjusted for participant
age, sex, years of education, MMSE total score, CDR global score, number of ApoE4
alleles, and scanner strength. To account for inter-individual differences in brain size, all
subcortical volumes were also adjusted for total intracranial volume. Significance of each
component was tested using 1000 permutations (p < 0.05). Significance of the variables
contributing to each component was assessed using 1000 bootstrapped samples (bootstrap
ratio > 2.0). Three different PLS-CA analyses were conducted with the subgroups
categorized as follows:
Analysis 1: Delusion Cohort (Binary Categorization). The first analysis categorized
patients with AD/MCI into two groups based on the presence or absence of symptoms of
delusions, irrespective of any other neuropsychiatric symptom. The two groups were
categorized as follows: 1) AD patients who never endorsed symptoms of delusions
throughout the duration of their ADNI visits (AD-D), and 2) AD or MCI patients who
endorsed symptoms of delusions at their baseline ADNI visit or who developed
symptoms of delusions over their disease course (AD+D)
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Analysis 2: Hallucination Cohort (Binary Categorization). The second analysis
categorized patients with AD/MCI into two groups based on the presence or absence of
hallucinations, irrespective of any other neuropsychiatric symptom. The two groups were
categorized as follows: 1) AD or MCI patients who never endorsed symptoms of
hallucinations throughout the duration of their ADNI visits (AD – H), and 2) AD or MCI
patients who endorsed symptoms of hallucinations at their baseline ADNI visit or who
developed symptoms of hallucinations over their disease course (AD+H).
Analysis 3: Combined Cohort (4 groups – to directly compare the interactions
between brain regions and SNPs in those with AD+D, AD+H, AD+DH and AD-DH).
The final analysis aggregated all patients with AD/MCI that had symptoms of
hallucinations and delusions, or the absence of these symptoms, into one analysis. In this
analysis, patients were categorized into four distinct groups: 1) AD patients who never
endorsed symptoms of delusions or hallucinations throughout the duration of their ADNI
visits (AD-DH); 2) AD or MCI patients who endorsed only symptoms of hallucinations at
their baseline ADNI visit or who developed symptoms of hallucinations over their disease
course (AD+H); 3) AD or MCI patients who endorsed only symptoms of delusions at
their baseline ADNI visit or who developed symptoms of delusions over their disease
course (AD+D), and 4) patients who endorsed symptoms of both delusions and
hallucinations (AD+DH), at the identified ADNI visit.
PLS-CA was conducted using R (Version 3.5.2) and the related statistic packages,
ExPosition and TExPosition (Beaton, Chin Fatt, & Abdi 2014; Beaton, Rieck, Fatt, &
Abdi, 2013), using the pipeline proposed in Beaton et al., 2015.

2.7.3 Principal Component Analysis and Binary Logistic Regression
To cross-validate brain regions identified by the PLS-CA, binary logistic regression
analyses for all participants with available imaging data (irrespective of GWAS
availability) were run for both the hallucination and delusion cohorts. Principal
component analysis (PCA) with varimax rotation and Kaiser normalization was used as a
dimension reduction technique to reduce the 82 ROIs into components. All cortical
thickness and subcortical volumes for each ROI were transformed into Z-scores across
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subjects prior to running the PCA. Following the PCA, the rotated component matrix was
inspected and any components that did not have any ROIs that loaded most strongly to a
particular component were excluded. The component scores for each retained component
were then entered into binary logistic regression models with the dependent variable
being either the presence/absence of delusions or the presence/absence of hallucinations.
Additional covariates in the model included age, years of education, sex, CDR global
score, MMSE total score, number of ApoE4 alleles and MRI scanner strength. Follow-up
logistic regression models were run by removing any variables that were not significant in
the prior model. Given the high degree of multicollinearity between ROIs in the identified
components, post-hoc analysis of covariance (ANCOVA) with FDR correction was used
to identify specific ROIs that may be contributing to the presence of
hallucinations/delusions.
PCA, binary logistic regression and post-hoc ANCOVAs were conducted using IBM
SPSS Statistics for Mac, Version 25.0.
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Chapter 3

3

Results
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3.1 Imaging and Genetics: PLS-CA Results
3.1.1

Delusion Cohort

A total of 188 participants were identified from the ADNI-1 database as meeting the
inclusion criteria. Of these, n=66 endorsed symptoms of delusions (AD+D), and n=122
did not endorse symptoms of delusions (AD-D). Independent samples t-test comparing
age, years of education, CDR global score, and MMSE total score, did not identify any
significant differences between the two groups. Additional chi-square tests did not
identify any group differences in sex distribution, MRI field strength, or number of
ApoE4 alleles (Table 3). The minor allele frequencies for the 15 SNPs of interest were
calculated for the entire cohort and are reported in Table 4.
Results of the PLS-CA did not identify any significant differences in interactions between
ROIs and SNPs that separated those with delusions from those without (Omnibus: p perm =
.118, Component 1: p perm = .161). Despite not reaching the threshold for significance,
Component 1 explained 40.45% of the variance in the dataset (Figure 1A). Although not
significant, the interaction of specific ROIs and SNPs that are more closely associated
with the delusion cohort, are ROIs with cortical thickness values below the grand mean
(ROIs below the horizontal axis in Figure 1B, see Table 5 for complete list of ROIs) and
SNPs that are to the left of the vertical axis in Figure 1B.
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Table 3. PLS-CA Delusion Cohort: Demographic and disease profile.
Delusions
(AD+D)
N = 66

No Delusions
(AD-D)
N = 122

Mean
(SD)
Mean
Age
75.94
6.6
76.07
Years of Education
15.18
2.9
15.16
CDR Global Score
0.88
0.43
0.92
MMSE Total Score
22.67
4.5
21.47
Males Females Males
Sex (%)
53.0
47.0
62.3
MRI Field Strength
1.5T
3T
1.5T
64
2
119
Delusions (AD+D)
Number of ApoE4 alleles
0
1
2
22
31
13

(SD)
7.1
3.1
0.43
4.3
Females
37.7
3T
3
0
41

t
p-value
0.1
.91
-0.06
.96
0.7
.51
-1.8
.075
Fischer's Exact Test (2-sided)
0.277
Fischer's Exact Test (2-sided)
1.00
No Delusions (AD-D)
1
2
58
23

Pearson Chi-Square
.99
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Table 4. PLS-CA - Delusion Cohort. Minor allele frequencies for the 15 SNPs of interest

Delusion Cohort PLS-CA, N=188
Gene

SNP

Minor Allele

Minor Allele Frequency

BCHE

rs1803274

T

0.170

CHRNA7

rs6494223

T

0.402

COMT

rs4680

A

0.484

DRD1

rs686

G

0.359

DRD2

rs1076560

A

0.830

DRD2

rs1800497

A

0.221

DRD2

rs6277

G

0.431

DRD3

rs6280

C

0.370

GRIN2A

rs9922678

A

0.330

GRIN2B

rs10845840

T

0.492

GRIN2B

rs1805502

G

0.156

GRIN2B

rs1806201

A

0.338

GRIN3A

rs10989591

T

0.293

GRIN3A

rs3739722

T

0.100

GRIN3B

rs3764650

G

0.080

ST108TA_minus

ST16SV_minus

ST94TA_minus

ST85TA_minus
ST90TA_minus

ST99TA_minus

ST91TA_minus

ST82TA_minus

ST95TA_minus
ST97TA_minus
ST98TA_minus

ST93TA_minus

ST83TA_minus
ST84TA_minus

ST75SV_minus
ST76SV_plus

ST73TA_plus

ST82TA_plus

ST95TA_plus
ST97TA_plus

Delusion Cohort − SNP BSR
ST91TA_plus

ST74TA_plus

ST99TA_plus

ST94TA_plus

ST85TA_plus
ST90TA_plus

ST72TA_plus
ST75SV_plus
ST83TA_plus
ST84TA_plus

ST98TA_plus

ST93TA_plus

ST76SV_minus

ST62TA_plus

0.64

ST70SV_plus
ST71SV_plus

5

ST73TA_minus

0.13

ST72TA_minus

4

ST56TA_plus
ST57TA_plus
ST58TA_plus
ST59TA_plus
ST60TA_plus

0.38

ST55TA_plus

ST49TA_plus
ST51TA_plus
ST52TA_plus

3

ST53SV_plus
ST54TA_plus

0.67

ST61SV_plus

ST46TA_plus
ST47TA_plus
ST50TA_plus

ST48TA_plus

ST40TA_plus

ST45TA_plus

ST43TA_plus

ST36TA_plus
ST38TA_plus
ST39TA_plus

ST26TA_plus
ST31TA_plus
ST32TA_plus
ST34TA_plus
ST35TA_plus

ST25TA_plus

ST15TA_plus

2

ST61SV_minus

ST44TA_plus

ST42SV_minus

ST24TA_plus

ST16SV_plus
ST23TA_plus

0.16

ST62TA_minus

ST54TA_minus

ST53SV_minus

ST44TA_minus

ST42SV_plus

ST17SV_plus

ST14TA_plus

ST121TA_plus
ST130TA_plus
ST13TA_plus

ST129TA_plus

ST120SV_plus

ST114TA_plus
ST115TA_plus
ST116TA_plus
ST117TA_plus
ST118TA_plus
ST119TA_plus

ST110TA_plus
ST111TA_plus

ST108TA_plus

1

ST70SV_minus
ST71SV_minus

ST48TA_minus
ST50TA_minus

ST46TA_minus
ST47TA_minus

ST43TA_minus

ST24TA_minus

ST14TA_minus
ST17SV_minus

ST12SV_plus

ST11SV_minus

ST102TA_plus
ST104TA_plus
ST105TA_plus
ST106TA_plus

P-value

ST55TA_minus
ST56TA_minus
ST57TA_minus
ST58TA_minus
ST59TA_minus
ST60TA_minus

ST51TA_minus
ST52TA_minus

ST49TA_minus

ST45TA_minus

ST25TA_minus
ST26TA_minus
ST31TA_minus
ST32TA_minus
ST34TA_minus
ST35TA_minus
ST36TA_minus
ST38TA_minus
ST39TA_minus
ST40TA_minus

ST23TA_minus

ST12SV_minus

ST11SV_plus

ST109TA_plus

ST107TA_plus

ST103TA_plus

ST112SV_plus
ST113TA_plus

ST101SV_minus

Component

ST74TA_minus

ST15TA_minus

ST130TA_minus
ST13TA_minus

ST129TA_minus

ST120SV_minus

ST101SV_plus

ST112SV_minus
ST113TA_minus

ST103TA_minus

ST109TA_minus

ST107TA_minus

ST119TA_minus
ST121TA_minus

ST114TA_minus
ST115TA_minus
ST116TA_minus
ST117TA_minus
ST118TA_minus

ST110TA_minus
ST111TA_minus

ST102TA_minus
ST104TA_minus
ST105TA_minus
ST106TA_minus
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Figure 1A.

Delusion Cohort
Omnibus p-value: .118

Delusion Cohort − Brain BSR

Figure 1B.
Figure 1C.
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GRIN3A_rs3739722.AA
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GRIN3A_rs3739722..a
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DRD2_rs1800497.AA
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DRD1_rs686.AA
DRD2_rs1076560..a

DRD1_rs686.Aa
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Figure 1. Delusion Cohort PLS-CA results. A. Component p-values and latent variable (LV) plot for Component 1.

The horizontal axis represents the SNPs and the vertical axis represents the brain regions of interest. Ellipsoids indicate

boot-strap confidence intervals (95%) B. Neuroimaging boot-strap regression results for Component 1 with blue bars

indicating significant brain regions. Red dashed line indicates the threshold for significance (+2 and -2) C. Single

nucleotide polymorphisms boot-strap regression results for Component 1 with blue bars indicating significant SNPs.
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Table 5. Delusion Cohort: Neuroimaging boot-strap regression, summary of ROIs with
cortical thickness values below the grand mean for Component 1.
Delusion Cohort - ROIs more closely associated with the delusion cohort
for Component 1
ST102TA_RightParacentral
ST102TA_RightParacentral
ST105TA_RightParsOrbitalis
ST106TA_RightParsTriangularis
ST108TA_RightPostCentral
ST110TA_RightPrecentral
ST111TA_RightPrecuneus
ST114TA_RightRostralMiddleFrontal
ST115TA_RightSuperiorFrontal
ST116TA_RightSuperiorParietal
ST117TA_RightSuperiorTemporal
ST118TA_RightSupramarginal
ST121TA_RightTransverseTemporal
ST130TA_RightInsula
ST15TA_LeftCaudalMiddleFrontal
ST26TA_LeftFusiform
ST31TA_LeftInferiorParietal
ST32TA_LeftInferiorTemporal
ST34TA_LeftIsthmusCingulate
ST35TA_LeftLateralOccipital
ST38TA_LeftLingual

ST40TA_LeftMiddleTemporal
ST43TA_LeftParacentral
ST45TA_LeftParsOpercularis
ST47TA_LeftParsTriangularis
ST49TA_LeftPostCentral
ST51TA_LeftPrecentral
ST52TA_LeftPrecuneus
ST55TA_LeftRostralMiddleFrontal
ST56TA_LeftSuperiorFrontal
ST57TA_LeftSuperiorParietal
ST58TA_LeftSuperiorTemporal
ST59TA_LeftSupramarginal
ST60TA_LeftTemporalPole
ST74TA_RightCaudalMiddleFrontal
ST82TA_RightCuneus
ST85TA_RightFusiform
ST90TA_RightInferiorParietal
ST91TA_RightInferiorTemporal
ST94TA_RightLateralOccipital
ST99TA_RightMiddleTemporal
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3.1.2

Hallucination Cohort

A total of 117 participants were identified from the ADNI-1 database as meeting the
inclusion criteria. Of these, n=36 endorsed symptoms of hallucinations (AD+H), and
n=81 did not endorse symptoms of hallucinations (AD-H). Independent samples t-test
comparing age, years of education, CDR global score, and MMSE total score, did not
identify any significant differences between the two groups. Additional chi-square tests
did not identify any group differences in sex distribution, MRI field strength, or number
of ApoE4 alleles (Table 6). The minor allele frequencies for the 15 SNPs of interest were
calculated for the entire cohort and are reported in Table 7.
Results of the PLS-CA identified a trend towards significance for Component 1, with the
interaction of ROIs and SNPs in Component 1 explaining 45.44% of the variance in the
dataset (Omnibus: p perm = .049, Component 1: p perm = .059; Figure 2A). Boot strap
analysis showed that cortical thickness and subcortical volumes below the grand mean for
bilateral frontal regions, bilateral cingulate regions, bilateral temporal regions, bilateral
fusiform, right entorhinal, left inferior parietal, right lingual, right precuneus, right insula,
and right accumbens area (Figure 2B; see Table 8 for complete list of ROIs) were
associated with the major homozygote of rs3764650 in GRIN3B, and the minor
homozygote of rs9922678 in GRIN2A (Figure 2C).This pattern of brain structure and
combination of SNPs was more closely associated with those with symptoms of
hallucinations when compared to those without.
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Table 6. PLS-CA Hallucination Cohort: Demographic and disease profile
No
Hallucinations
(AD-H)
N = 81
Mean
(SD)
Mean
(SD)
t
p-value
74.89
7.1
75.85
6.2
.74
.46
14.56
3.1
15.44
2.9
1.5
.14
1.28
0.61
1.12
0.33
-1.42
.16
20.22
5.4
20.77
4.4
.57
.57
Males Females Males Females Fischer's Exact Test (2-sided)
52.8
47.2
58.0
42.0
0.687
1.5T
3T
1.5T
3T
Fischer's Exact Test (2-sided)
36
0
78
3
0.552
Hallucinations (AD+H)
No Hallucinations (AD-H)
Hallucinations
(AD+H)
N = 36

Age
Years of Education
CDR Global Score
MMSE Total Score
Sex (%)
MRI Field Strength

Number of ApoE4 alleles

0
10

1
21

2
5

0
25

1
39

2
17

Pearson Chi-Square
.54

Table 7. PLS-CA - Hallucination Cohort. Minor allele frequencies for the 15 SNPs of
interest.
Hallucination Cohort N = 117
Gene

SNP

Minor Allele

Minor Allele Frequency

BCHE
CHRNA7

rs1803274
rs6494223

T
T

0.171
0.427

COMT

rs4680

A

0.483

DRD1
DRD2
DRD2
DRD2

rs686
rs1076560
rs1800497
rs6277

G
A
A
G

0.371
0.171
0.235
0.432

DRD3
GRIN2A
GRIN2B
GRIN2B

rs6280
rs9922678
rs10845840
rs1805502

C
A
C
G

0.346
0.329
0.470
0.141

GRIN2B
GRIN3A
GRIN3A
GRIN3B

rs1806201
rs10989591
rs3739722
rs3764650

A
T
T
G

0.350
0.303
0.120
0.081

ST130TA_minus

ST99TA_minus

ST85TA_minus
ST90TA_minus

ST82TA_minus

ST94TA_minus

ST84TA_minus

ST97TA_minus
ST98TA_minus

ST93TA_minus

ST83TA_minus

ST75SV_minus
ST76SV_plus

ST76SV_minus

ST94TA_plus

ST82TA_plus

ST75SV_plus

ST97TA_plus
ST98TA_plus

ST93TA_plus

ST85TA_plus
ST90TA_plus

ST84TA_plus

Hallucination Cohort − SNP BSR
ST99TA_plus

ST95TA_plus

ST91TA_plus

ST83TA_plus

ST74TA_plus

ST62TA_plus
ST70SV_plus

0.17

ST71SV_plus
ST72TA_plus

5

ST73TA_plus

0.43

ST73TA_minus

4

ST74TA_minus

ST61SV_plus

ST56TA_plus

0.17

ST60TA_plus

3

ST58TA_plus
ST59TA_plus

ST54TA_plus
ST55TA_plus

ST49TA_plus
ST50TA_plus
ST51TA_plus
ST52TA_plus

0.20

ST57TA_plus

ST34TA_plus

ST45TA_plus
ST46TA_plus

ST39TA_plus
ST40TA_plus

ST15TA_plus

ST121TA_plus
ST130TA_plus

2

ST71SV_minus
ST72TA_minus

ST48TA_plus

ST53SV_plus

ST26TA_plus
ST31TA_plus
ST32TA_plus

ST24TA_plus

ST36TA_plus

ST43TA_plus

ST38TA_plus

ST35TA_plus

ST25TA_plus

ST23TA_plus

ST42SV_plus

ST61SV_minus

ST44TA_minus

ST104TA_plus
ST105TA_plus
ST106TA_plus

0.06

ST62TA_minus
ST70SV_minus

ST57TA_minus

ST53SV_minus

ST44TA_plus

ST42SV_minus

ST12SV_plus
ST13TA_plus
ST14TA_plus
ST16SV_plus
ST17SV_minus

ST108TA_plus

1

ST58TA_minus
ST59TA_minus
ST60TA_minus

ST54TA_minus
ST55TA_minus
ST56TA_minus

ST49TA_minus
ST50TA_minus
ST51TA_minus
ST52TA_minus

ST48TA_minus

ST43TA_minus

ST36TA_minus
ST38TA_minus

ST35TA_minus

ST17SV_plus

ST102TA_plus

ST109TA_plus
ST110TA_plus
ST111TA_plus
ST112SV_plus
ST113TA_plus
ST114TA_plus
ST115TA_plus
ST116TA_plus
ST117TA_plus
ST118TA_plus
ST119TA_plus

ST107TA_plus

ST103TA_plus

ST11SV_plus
ST120SV_plus

ST101SV_plus

P-value

ST95TA_minus

ST39TA_minus
ST40TA_minus

ST23TA_minus
ST25TA_minus

ST11SV_minus
ST120SV_minus

ST16SV_minus

ST13TA_minus
ST14TA_minus

ST12SV_minus

ST116TA_minus

ST101SV_minus

Component

ST91TA_minus

ST24TA_minus
ST26TA_minus
ST31TA_minus
ST32TA_minus

ST45TA_minus
ST46TA_minus

ST34TA_minus

ST107TA_minus

ST112SV_minus
ST113TA_minus

ST108TA_minus

ST102TA_minus
ST103TA_minus

Figure 2B.

ST15TA_minus

ST121TA_minus

ST118TA_minus
ST119TA_minus

ST117TA_minus

ST114TA_minus
ST115TA_minus

ST109TA_minus
ST110TA_minus
ST111TA_minus

ST104TA_minus
ST105TA_minus
ST106TA_minus
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Figure 2A.
Hallucination Cohort
Omnibus p-value: .049

Hallucination Cohort − Brain BSR

Figure 2C.
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Figure 2. Hallucination Cohort PLS-CA results. A. Component p-values and latent variable (LV) plot for

Component 1. The horizontal axis represents the SNPs and the vertical axis represents the brain regions of

interest. Ellipsoids indicate boot-strap confidence intervals (95%) B. Neuroimaging boot-strap regression results

for Component 1 with blue bars indicating significant cortical regions and red bars indicating significant

subcortical regions. Red dashed line indicates the threshold for significance (+2 and -2) C. Single nucleotide

polymorphisms boot-strap regression results for Component 1 with blue bars indicating significant SNPs.
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Table 8. Hallucination Cohort: Neuroimaging boot-strap regression, summary of
significant ROIs with cortical thickness values below the grand mean for Component 1.
Hallucination Cohort - Significant ROIs with cortical thickness and
subcortical volumes below the grand mean.
ST104TA_RightParsOpercularis
ST105TA_RightParsOrbitalis
ST106TA_RightParsTriangularis
ST109TA_RightPosteriorCingulate
ST110TA_RightPrecentral
ST111TA_RightPrecuneus
ST114TA_RightRostralMiddleFrontal
ST15TA_LeftCaudalMiddleFrontal
ST117TA_RightSuperiorTemporal
ST118TA_RightSupramarginal
ST119TA_RightTemporalPole
ST121TA_RightTransverseTemporal
ST130TA_RightInsula
ST15TA_LeftCaudalMiddleFrontal
ST26TA_LeftFusiform
ST31TA_LeftInferiorParietal
ST34TA_LeftIsthmusCingulate
ST39TA_LeftMedialOrbitofrontal
ST40TA_LeftMiddleTemporal

ST45TA_LeftParsOpercularis
ST46TA_LeftParsOrbitalis
ST49TA_LeftPostCentral
ST51TA_LeftPrecentral
ST56TA_LeftSuperiorFrontal
ST58TA_LeftSuperiorTemporal
ST59TA_LeftSupramarginal
ST62TA_LeftTransverseTemporal
ST74TA_RightCaudalMiddleFrontal
ST83TA_RightEntorhinal
ST85TA_RightFusiform
ST91TA_RightInferiorTemporal
ST93TA_RightIsthmusCingulate
ST95TA_RightLateralOrbitofrontal
ST97TA_RightLingual
ST99TA_RightMiddleTemporal
ST70SV_RightAccumbensArea
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3.1.3

Combined Cohort

A total of 207 participants were identified from the ADNI-1 database as meeting the
inclusion criteria. Of these, n=21 endorsed symptoms of hallucinations only (AD+H),
n=54 endorsed symptoms of delusions only (AD+D), n=10 endorsed symptoms of both
hallucinations and delusions (AD+DH), and n=116 did not endorse symptoms of
hallucinations (AD-H). A Kruskal-Wallis test with Bonferroni correction of between
group differences identified a significant difference in CDR global score between the
groups, with the AD+H group having on average a greater CDR score (higher disease
severity) than the AD+D group (p=.017). A significant difference was also identified for
MMSE total scores, with the AD+H group having on average lower total scores on the
MMSE than the AD+D group (p=.022). No significant between group differences were
identified for the other cohorts of interest (Table 9). The minor allele frequencies for the
15 SNPs of interest were calculated for the entire cohort and are reported in Table 10.
Results of the PLS-CA identified a trend towards significance for Component 1
(Omnibus: p perm = .057, Component 1: p perm = .071; Figure 3A), with the interaction of
ROIs and SNPs in Component 1 explaining 44.16% of the variance in the dataset. (Figure
3A). Boot strap analysis showed that cortical thickness values below the grand mean for a
number of bilateral frontal regions, bilateral temporal regions, bilateral parietal regions,
bilateral fusiform, right entorhinal, left isthmus cingulate, left posterior cingulate, bilateral
precuneus, right cuneus, left lingual, bilateral lateral occipital, and bilateral insula (Figure
3B; see Table 11 for complete list of ROIs), were associated with the major homozygotes
of rs3764650 in GRIN3B and rs1803274 in BCHE, the minor homozygote/heterozygote
of rs1805502 in GRIN2B, and with the minor homozygote of rs9922678 in GRIN2A
(Figure 3C). This pattern of brain structure and combination of genotypes was more
closely associated with the AD+DH group than with any other group. In contrast, cortical
thickness values above the grand mean for the aforementioned ROIs were more closely
associated with the major homozygote of rs1805502 in GRIN2B, the minor
homozygote/heterozygote of rs3764650 in GRIN3B, and the minor
homozygote/heterozygote of rs1803274 in BCHE. Moreover, this pattern of brain
structure and combination of genotypes was more closely associated with the AD+H
group than with any other group.

Table 9. PLS-CA Combined Cohort: Demographic and disease profile
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Table 10. PLS-CA - Combined Cohort. Minor allele frequencies for the 15 SNPs of
interest

Combined Cohort PLS-CA, N=201
Gene

SNP

Minor Allele

Minor Allele Frequency

BCHE

rs1803274

T

0.177

CHRNA7

rs6494223

T

0.415

COMT

rs4680

A

0.485

DRD1

rs686

G

0.363

DRD2

rs1076560

A

0.167

DRD2

rs1800497

A

0.213

DRD2

rs6277

G

0.430

DRD3

rs6280

C

0.356

GRIN2A

rs9922678

A

0.324

GRIN2B

rs10845840

C

0.495

GRIN2B

rs1805502

G

0.152

GRIN2B

rs1806201

A

0.326

GRIN3A

rs10989591

T

0.286

GRIN3A

rs3739722

T

0.102

GRIN3B

rs3764650

G

0.090

SNPs.

ST111TA_minus

ST95TA_minus
ST97TA_minus
ST98TA_minus

ST93TA_minus

ST84TA_minus

ST76SV_plus

ST70SV_plus
ST71SV_plus
ST72TA_plus

ST97TA_plus
ST98TA_plus

ST93TA_plus

ST84TA_plus

ST75SV_plus
ST76SV_minus

ST73TA_plus

ST91TA_plus

ST85TA_plus

ST74TA_plus

ST99TA_plus

ST94TA_plus
ST95TA_plus

ST90TA_plus

ST82TA_plus
ST83TA_plus
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ST99TA_minus

ST94TA_minus

ST85TA_minus
ST90TA_minus

ST82TA_minus
ST83TA_minus

ST75SV_minus

ST73TA_minus

ST70SV_minus
ST71SV_minus

0.81

ST58TA_plus
ST59TA_plus
ST60TA_plus

5

ST62TA_plus

0.39

ST61SV_minus

ST55TA_plus
ST56TA_plus

4

ST57TA_plus

0.33

ST72TA_minus

ST61SV_plus

ST54TA_plus

ST49TA_plus

ST52TA_plus

3

ST60TA_minus

ST54TA_minus

ST50TA_plus
ST51TA_plus

ST46TA_plus
ST47TA_plus

ST45TA_plus

0.63

ST55TA_minus

ST53SV_plus

ST48TA_plus

ST43TA_plus

ST36TA_plus
ST38TA_plus
ST39TA_plus
ST40TA_plus

2

ST57TA_minus
ST58TA_minus

ST53SV_minus

ST44TA_plus

ST42SV_minus

ST26TA_plus
ST31TA_plus
ST32TA_plus
ST34TA_plus
ST35TA_plus

ST15TA_plus

ST130TA_plus

ST121TA_plus

ST114TA_plus
ST115TA_plus
ST116TA_plus
ST117TA_plus
ST118TA_plus
ST119TA_plus

ST129TA_plus

ST24TA_plus

ST106TA_plus

ST110TA_plus
ST111TA_plus

ST108TA_plus

0.07

ST56TA_minus

ST48TA_minus

ST44TA_minus

ST42SV_plus

ST25TA_plus

ST23TA_plus

ST16SV_plus

ST13TA_plus

ST120SV_plus

ST17SV_minus

ST14TA_plus

ST12SV_plus

ST109TA_plus

ST104TA_plus
ST105TA_plus

ST102TA_plus

1

ST62TA_minus

ST45TA_minus
ST46TA_minus
ST47TA_minus

ST43TA_minus

ST36TA_minus
ST38TA_minus
ST39TA_minus

ST50TA_minus
ST51TA_minus
ST52TA_minus

ST49TA_minus

ST40TA_minus

ST17SV_plus

ST14TA_minus

ST12SV_minus

ST11SV_minus

ST103TA_plus

ST107TA_plus

ST112SV_plus
ST113TA_plus

ST101SV_minus

P-value

ST91TA_minus

ST26TA_minus

ST32TA_minus
ST34TA_minus
ST35TA_minus

ST31TA_minus

ST23TA_minus
ST24TA_minus
ST25TA_minus

ST16SV_minus

ST120SV_minus

ST11SV_plus

ST101SV_plus

ST112SV_minus
ST113TA_minus

ST13TA_minus

ST109TA_minus

ST107TA_minus

ST103TA_minus

Component

ST59TA_minus

ST15TA_minus

ST130TA_minus

ST119TA_minus

ST102TA_minus

ST121TA_minus
ST129TA_minus

ST114TA_minus
ST115TA_minus
ST116TA_minus
ST117TA_minus
ST118TA_minus

ST110TA_minus

ST108TA_minus

ST104TA_minus
ST105TA_minus
ST106TA_minus
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Figure 3A.
Combined Cohort
Omnibus p-value: .057

Combined Cohort − Brain BSR

Figure 3C.

Cortical

NS

Figure 3. Combined Cohort PLS-CA results. A. Component p-values and latent variable (LV) plot for Component 1.

The horizontal axis represents the SNPs and the vertical axis represents the brain regions of interest. Ellipsoids

indicate boot-strap confidence intervals (95%) B. Neuroimaging boot-strap regression results for Component 1 with

blue bars indicating significant brain regions. Red dashed line indicates the threshold for significance (+2 and -2) C.

Single nucleotide polymorphisms boot-strap regression results for Component 1 with blue bars indicating significant
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Table 11. Combined Cohort: Neuroimaging boot-strap regression, summary of
significant ROIs with cortical thickness values below the grand mean for Component 1.
Combined Cohort - Significant ROIs with cortical thickness values below the grand mean
ST102TA_RightParacentral
ST43TA_LeftParacentral
ST104TA_RightParsOpercularis
ST45TA_LeftParsOpercularis
ST105TA_RightParsOrbitalis
ST46TA_LeftParsOrbitalis
ST106TA_RightParsTriangularis
ST47TA_LeftParsTriangularis
ST108TA_RightPostCentral
ST49TA_LeftPostCentral
ST110TA_RightPrecentral
ST50TA_LeftPosteriorCingulate
ST111TA_RightPrecuneus
ST51TA_LeftPrecentral
ST114TA_RightRostralMiddleFrontal
ST52TA_LeftPrecuneus
ST115TA_RightSuperiorFrontal
ST55TA_LeftRostralMiddleFrontal
ST116TA_RightSuperiorParietal
ST56TA_LeftSuperiorFrontal
ST117TA_RightSuperiorTemporal
ST57TA_LeftSuperiorParietal
ST118TA_RightSupramarginal
ST58TA_LeftSuperiorTemporal
ST119TA_RightTemporalPole
ST59TA_LeftSupramarginal
ST121TA_RightTransverseTemporal
ST60TA_LeftTemporalPole
ST129TA_LeftInsula
ST74TA_RightCaudalMiddleFrontal
ST130TA_RightInsula
ST82TA_RightCuneus
ST15TA_LeftCaudalMiddleFrontal
ST83TA_RightEntorhinal
ST26TA_LeftFusiform
ST85TA_RightFusiform
ST31TA_LeftInferiorParietal
ST90TA_RightInferiorParietal
ST32TA_LeftInferiorTemporal
ST91TA_RightInferiorTemporal
ST34TA_LeftIsthmusCingulate
ST94TA_RightLateralOccipital
ST35TA_LeftLateralOccipital
ST95TA_RightLateralOrbitofrontal
ST38TA_LeftLingual
ST99TA_RightMiddleTemporal
ST39TA_LeftMedialOrbitofrontal
ST40TA_LeftMiddleTemporal
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3.2 Neuroimaging Only Analysis
3.2.1 Delusion Cohort
A total of 363 participants were identified from the ADNI database as meeting the
inclusion criteria. Of these, n=143 endorsed symptoms of delusions (AD+D), and n=220
did not endorse symptoms of delusions (AD-D). Independent samples t-test comparing
age, years of education, CDR global score, and MMSE total score identified a significant
difference in MMSE total score between the two groups (p <.001), with the AD+D group
on average having higher scores than the AD-D group. No significant differences were
identified for any of the other covariates. Additional chi-square tests did not identify any
group differences in sex distribution, MRI field strength, or number of ApoE4 alleles
(Table 12).
A principal component analysis was conducted on the z-scores of 82 regions of interest
with orthogonal rotation (varimax). The Kaiser-Meyer-Olkin measure verified the
sampling adequacy for the analysis, KMO = .95. The rotation converged in 11 iterations
and 13 components were identified that had eigenvalues over Kaiser’s criterion of 1 and
in combination explained 75.35% of the variance. The rotated component matrix was then
used to identify ROIs that loaded most strongly to each component. No ROI loaded most
strongly to component 12 and as such only components 1-11, 13 were retained for
subsequent analyses. The 12 retained components reflected the following regions: 1)
Bilateral frontal, parietal, occipital, and temporal, 2) bilateral orbitofrontal, middle
frontal, frontal pole, orbitalis, 3) bilateral entorhinal cortex, amygdala, temporal pole,
parahippocampal, insula, 4) left inferior, superior, middle, fusiform, isthmus cingulate, 5)
bilateral caudal ACC, rostral ACC, posterior cingulate, right isthmus cingulate, 6)
bilateral lingual, cuneus, pericalcarine, 7) right inferior temporal, superior temporal,
middle temporal, fusiform, 8) bilateral pallidum, putamen, 9) bilateral caudate, 10)
bilateral cerebellum, 11) bilateral thalamus, 13) bilateral accumbens area (Table 13).
Component scores for each participant were also extracted for subsequent analyses.
The initial logistic regression analysis included the component scores for the 12
components described above in addition to the following covariates, age, sex, years of
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education, CDR global score, MMSE total score, number of APOE4 alleles, and scanner
strength. The overall model was significant χ2(20) = 33.01, p = .034. The model
explained 11.8 % (Nagelkerke R2) of the variance in delusions and correctly classified
66.9% of cases. The Wald criterion demonstrated that MMSE total scores (p= .004,
Exp(B)=1.11 (95%CI: 1.04-1.20) made significant contributions to the presence of
delusions. Trends towards significance were also identified for Component 2 (p= .068,
Exp(B)=.80 (95%CI: .63-1.02), and Component 3 (p=.074, Exp(B)= 1.26 (95%CI: .981.62).
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Table 12. Imaging only analysis: Delusion cohort demographic and disease profile

Age
Years of Education
CDR Global Score
MMSE Total Score
Sex (%)
MRI Field Strength

Number of ApoE4 alleles

Delusions
No Delusions
(AD+D)
(AD-D)
N = 143
N = 220
Mean
(SD)
Mean
(SD)
74.80
7.2
75.94
7.3
15.31
3.0
15.18
2.8
0.90
0.46
0.93
0.42
22.94
4.3
21.28
4.2
Males Females Males Females
52.4
47.6
58.6
41.4
1.5T
3T
1.5T
3T
89
54
150
70
Delusions (AD+D)
0
1
2

0

42

75

72

29

t
p-value
1.5
.15
-0.41
.69
0.64
.52
-3.66
<.001
Fischer's Exact Test (2-sided)
0.279
Fischer's Exact Test (2-sided)
0.259
No Delusions (AD-D)
1
2
100
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Pearson Chi-Square
.595
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Table 13. Delusion Cohort: Rotated component matrix. Colours indicate ROIs loading most strongly to each
component based on component scores. Loadings below 0.3 have been suppressed. R = Right, L=Left.
Components
FreeSurfer ROIs

1

2

3

4

R Precentral

0.85

R Superior Parietal

0.83

R PostCentral

0.825

L Precentral

0.824

L Post Central

0.807

R Paracentral

0.803

R Caudal Middle Frontal

0.799

L Superior Parietal

0.795

L Paracentral

0.791

R Precuneus

0.79

R Supramarginal

0.77

L Precuneus

0.767

L Caudal Middle Frontal

0.766

R Inferior Parietal

0.757

L Superior Frontal

0.717

L Supramarginal

0.703

0.439

L Inferior Parietal

0.688

0.521

R Superior Frontal

0.677

R Lateral Occipital

0.615

R Pars Opercularis

0.606

R Bank STS

0.601

L Pars Opercularis

0.569

0.481

R Pars Triangularis

0.552

0.542

L Lateral Occipital

0.546

L Transverse Temporal

0.48

R Transverse Temporal

0.447

7

8

9

10

11

12

0.383
0.362
0.313

0.324
0.413

0.481

0.555
0.472

0.306

0.451
0.482

0.388

0.496
0.431

0.303
0.746

L Lateral Orbitofrontal

0.719

L Pars Orbitalis

0.702

R Frontal Pole

0.702

L Frontal Pole

0.691

R Pars Orbitalis

0.682
0.571

6

0.322

R Lateral Orbitofrontal

R Rostral Middle Frontal

5

0.39
0.3

0.653

R Medial Orbitofrontal

0.652

0.304

L Medial Orbitofrontal

0.646

0.301

13
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L Rostral Middle Frontal

0.562

0.645

L Pars Triangularis

0.472

0.552

L Entorhinal

0.791

R Entorhinal

0.761

R Amygdala

0.704

R Temporal Pole

0.692

L Amygdala

0.689

L Temporal Pole

0.648

L Parahippocampal

0.549

0.362

R Parahippocampal

0.541

0.356

0.44

0.403

0.341

R Insula

0.32

L Inferior Temporal

0.336
0.305

0.351

0.405

0.712

L Middle Temporal

0.474

0.672

L Bank STS

0.524

0.589

L Fusiform

0.384

0.342

0.581

L Superior Temporal

0.452

0.384

0.488

L Isthmus Cingulate

0.388

0.4

0.382
0.669

L Caudal Anterior Cingulate
0.331

L Rostral Anterior Cingulate

0.651
0.606

R Caudal Anterior Cingulate
L Posterior Cingulate

0.454

0.579

R Posterior Cingulate

0.462

0.568
0.361

R Rostral Anterior Cingulate

0.495

R Isthmus Cingulate

0.323

0.495

L Insula

0.305

L Lingual

0.435

R Cuneus

0.554

0.628

R Lingual

0.458

0.615

R Pericalcarine

0.512

0.611

L Cuneus

0.517

0.597

L Pericalcarine

0.518

0.566

R Inferior Temporal

0.304

0.393

0.643

R Middle Temporal

0.461

0.355

0.622

R Superior Temporal

0.493

0.415

0.521

R Fusiform

0.429

0.417

0.494

0.308

0.395

0.306
0.315

-0.342

0.402
0.629

L Pallidum

0.784

R Pallidum

0.74

R Putamen

0.636

0.509

L Putamen

0.633

0.461

50

L Caudate

0.877

R Caudate

0.875

R Cerebellum Cortex

0.903

L Cerebellum Cortex

0.896

R Thalamus

0.901

L Thalamus

0.892
0.801

L Accumbens Area
R Accumbens Area

0.419

0.581
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3.2.1 Hallucination Cohort
A total of 233 participants were identified from the ADNI database as meeting the
inclusion criteria. Of these, n=84 endorsed symptoms of hallucinations (AD+H), and
n=149 did not endorse symptoms of hallucination (AD-H). Independent samples t-test
comparing age, years of education, CDR global score, and MMSE total score did not
identify any significant differences between the two groups. Additional chi-square tests
did not identify any group differences in sex distribution, MRI field strength, or number
of ApoE4 alleles (Table 14).
A principal component analysis was conducted on the z-scores of 82 regions of interest
with orthogonal rotation (varimax). The Kaiser-Meyer-Olkin measure verified the
sampling adequacy for the analysis, KMO = .94. The rotation converged in 12 iterations
and 13 components were identified that had eigenvalues over Kaiser’s criterion of 1 and
in combination explained 76.63% of the variance. The rotated component matrix was then
used to identify ROIs that loaded most strongly to each component. No ROI loaded most
strongly to component 13 and as such only the first 12 components were retained for
subsequent analyses. The 12 retained components reflected the following regions: 1)
bilateral frontal, parietal and occipital regions, 2) bilateral orbital frontal, middle frontal
regions, 3) bilateral entorhinal cortex, amygdala, temporal poles, parahippocampal,
insula, 4) left middle temporal, inferior temporal, superior temporal, fusiform, isthmus
cingulate, 5) right superior, inferior and middle temporal, 6) bilateral lingual and right
pericalcarine, 7) bilateral caudal ACC, left ACC, left posterior cingulate, 8) bilateral
pallidum, putamen, 9) bilateral caudate, 10) bilateral cerebellum, 11) bilateral thalamus,
12) bilateral accumbens area (Table 15). Component scores for each participant were also
extracted for subsequent analyses.
The initial logistic regression analysis included the component scores for the 12
components described above in addition to the following covariates, age, sex, years of
education, CDR global score, MMSE total score, number of APOE4 alleles, and scanner
strength. The overall model was significant χ2(20) = 43.39 p = .002. The model explained
23.3 % (Nagelkerke R2) of the variance in hallucinations and correctly classified 72.5% of
cases. The Wald criterion demonstrated that Component 1 (p = .028, Exp(B) = 1.52
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(95%CI: 1.05 - 2.20)), Component 2 (p=.012, Exp(B) = .644 (95%CI: 0.46 - 0.91)),
Component 3 (p=.009, Exp(B) = 1.61 (95%CI: 1.13 – 2.29)), and Component 7 (p=.002,
Exp(B)=.595 (95%CI: 0.43-0.83), made significant contributions to the presence of
hallucinations. A follow-up logistic regression was conducted including only the
variables that were identified as significant in the previous analysis. This included
component scores for Components 1, 2, 3, 7. The overall model was significant χ2(4) =
34.11, p < .001. The model explained 18.7% (Nagelkerke R2) of the variance in
hallucinations and correctly classified 72.1% of cases. The Wald criterion demonstrated
that Component 1 (p = .003, Exp(B) = 1.59 (95%CI: 1.18 - 2.12)), Component 2 (p=.024,
Exp(B) = .699 (95%CI: 0.51 - 0.96)), and Component 3 (p=.001, Exp(B) = 1.67 (95%CI:
1.23 – 2.25)), Component 7 (p=.003, Exp(B)=.622 (95%CI: 0.46-0.85), made significant
contributions to the presence of hallucinations..
Post-hoc analysis of covariance with FDR correction (q<.010) compared the mean
cortical thickness and subcortical volumes for ROIs loading most strongly to Components
1, 2, 3, 7 between the AD+H and AD-H groups, with sex, age, years of education, CDR
global score, and MMSE total score as covariates. Trends of larger cortical thickness
were found for AD+H compared to AD-H in the following regions: left superior parietal
(F(1,224)=4.31, p = .039, q = 0.307), left post central (F(1,224)=5.03, p =.026, q = .307),
left cuneus (F(1,224)=4.1, p = .044, q = .307), left entorhinal (F(1,224)=6.5, p = .011, q =
.055), right entorhinal (F(1,224)=6.9, p = .009, q = .055), left amygdala (F(1,224)=4.10, p
= .044, q = .147). Trends for smaller cortical thickness for AD+H compared to AD-H
were found in the following regions: left lateral orbitofrontal (F(1,224)=6.48, p = .012, q
= .110), left medial orbitofrontal(F(1,224)=5.39 p = .021, q =. 110), right medial
orbitofrontal (F(1,224)=4.7, p = .031, q = .116), and the right frontal pole (F(1,224)=5.32,
p = .022, q = .110). Regions that were found to have significantly smaller cortical
thickness values in AD+H subjects when compared to AD-H subjects included the left
rostral anterior cingulate (F(1,224)=5.12, p = .025, q = .033), left caudal anterior
cingulate (F(1,224)=10.25, p = .002, q = .004), and the right caudal anterior cingulate
(F(1,224)=10.81, p = .001, q = .004).
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Table 14. Imaging only analysis: Hallucination cohort demographic and disease profile
No
Hallucinations
(AD-H)
N = 149
Mean
(SD)
Mean
(SD)
t
p-value
Age
73.61
7.3
75.31
6.7
-1.8
0.07
Years of Education
14.87
3.0
15.38
2.7
-1.3
0.19
CDR Global Score
1.12
0.57
1.11
0.32
0.07
0.94
MMSE Total Score
21.26
5.3
20.48
4.3
1.2
0.22
Males Females Males Females Fischer's Exact Test (2-sided)
Sex (%)
52.4
47.6
54.4
45.6
0.786
MRI Field Strength
1.5T
3T
1.5T
3T
Fischer's Exact Test (2-sided)
50
34
104
45
0.116
Hallucinations (AD+H)
No Hallucinations (AD-H)
Number of ApoE4 alleles
0
1
2
0
1
2
22
45
17
47
69
33
Hallucinations
(AD+H)
N = 84

Pearson Chi-Square
.552
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Table 15. Hallucination Cohort: Rotated component matrix. Colours indicate ROIs
loading most strongly to each component based on component scores. Loadings below
0.3 have been suppressed. R = Right, L=Left
Components
FreeSurfer ROIs

1

2

3

4

5

6

R Superior Parietal

0.849

L Superior Parietal

0.837

R Precentral

0.825

R Precuneus

0.824

L Paracentral

0.818

L Precentral

0.818

R Paracentral

0.811

L PostCentral

0.804

R PostCentral

0.802

L Precuneus

0.779

R Caudal Middle Frontal

0.775

0.338

L Caudal Middle Frontal

0.773

0.337

R Inferior Parietal

0.772

L Inferior Parietal

0.734

R Supramarginal

0.728

L Supramarginal

0.705

0.325

L Superior Frontal

0.692

0.532

R Superior Frontal

0.671

0.577

R Cuneus

0.652

0.55

R Lateral Occipital

0.642

0.433

R Bank STS

0.607

L Cuneus

0.598

R Pars Opercularis

0.583

L Lateral Occipital

0.563

L Pericalcarine

0.557

R Fusiform

0.502

R Posterior Cingulate

0.495

0.321

L Transverse Temporal

0.445

0.377

R Isthmus Cingulate

0.388

0.382

7

0.34
0.365
0.405
0.507
0.43
0.433

0.529
0.513
0.501
0.375

0.498
0.516

0.417

R Lateral Orbitofrontal

0.782

L Pars Orbitalis

0.781

L Lateral Orbitofrontal

0.745

R Pars Orbitalis

0.688

0.387
0.46
0.333

8

9

10

11

12
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R Rostral Middle Frontal

0.499

0.687

R Frontal Pole

0.687

L Medial Orbitofrontal

0.686

L Rostral Middle Frontal

0.523

0.664

R Medial Orbitofrontal

0.653

L Frontal Pole

0.64

R Pars Triangularis

0.505

0.607

L Pars Triangularis

0.468

0.599

L Pars Opercularis

0.537

0.544

0.359

0.488

R Rostral Anterior Cingulate
R Transverse Temporal

0.315

0.414

0.348

0.419

0.362

L Entorhinal

0.765

R Entorhinal

0.756
0.377

R Temporal Pole

0.7

L Amygdala

0.698

R Amygdala

0.678
0.387

L Temporal Pole
R Parahippocampal

0.332

0.611

0.31

0.499
0.492

L Parahippocampal
L Insula

0.415

0.422

R Insula

0.409

0.471

0.36
0.472

0.309

0.721

L Inferior Temporal
L Middle Temporal

0.432

0.305

0.706

L Fusiform

0.404

L Bank STS

0.548

L Superior Temporal

0.407

0.34

L Isthmus Cingulate

0.378

0.308

R Superior Temporal

0.492

0.375

0.582

R Middle Temporal

0.515

0.329

0.577

R Inferior Temporal

0.389

0.381

0.542

L Lingual

0.455

R Pericalcarine

0.53

0.591

R Lingual

0.524

0.571

0.331

0.579
0.566

0.325

0.33

0.542
0.495

0.341

0.365

L Rostral Anterior Cingulate

0.636

0.713

L Caudal Anterior Cingulate

0.699

R Caudal Anterior Cingulate

0.522

L Posterior Cingulate

0.48

0.316

0.489

R Pallidum

0.763

L Pallidum

0.76
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R Putamen

0.608

0.451

L Putamen

0.554

0.45

L Caudate

0.881

R Caudate

0.871

0.302

L Cerebellum Cortex

0.891

R Cerebellum Cortex

0.888

R Thalamus

0.854

L Thalamus

0.853
0.712

L Accumbens Area
R Accumbens Area

0.325

0.644
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4.1 Discussion Overview
The biological mechanisms underlying psychotic symptoms in AD are poorly understood.
Some patients with AD develop psychotic symptoms early in their disease course while
others remain asymptomatic throughout. The discrepancy between participants that
present with psychotic symptoms and those that do not provides an opportunity to
investigate differences between these two groups of AD patients. In particular, it allows
us to compare differences in neuroanatomical structures and genetic variants that could
potentially mediate the presence of these symptoms in AD. As such, in our study we
sought to investigate if the interactions between regional brain changes and genetic
polymorphisms in neurotransmitter systems may be associated with the presence of
delusions and hallucinations in AD.
Using PLS-CA we simultaneously assessed the interaction between 82 subcortical and
cortical regions of interest and 15 SNPs in neurotransmitter systems to determine whether
unique patterns of interactions may separate those with delusions, those with
hallucinations, and those with both symptoms. Follow-up binary logistic regression
analyses from a larger available sample were used to identify specific brain regions
associated with the presence or absence of psychotic symptoms. For the delusion cohorts,
results of the PLS-CA suggest that there are no significant interactions between
neuroanatomical and genetic factors that distinguish those with delusions when compared
to those without. In contrast, for the logistic regression analysis, although not significant
we did identify a trend towards significance which suggests that cortical atrophy to
orbitofrontal and middle frontal regions, coupled with relative preservation of temporal
lobe structures may be associated with symptoms of delusions. The results for the PLSCA for the hallucination cohort, suggest that individuals with AD and hallucinations may
have a unique pattern of interactions in cortical regions and SNPs within the
glutamatergic system when compared to those without hallucinations. Moreover, those
with AD and symptoms of both delusions and hallucinations may have a distinct profile
from those with just hallucinations even when matched for disease severity. Collectively,
our findings suggest that delusions and hallucinations in AD may be associated with
unique underlying neuroanatomic and genetic correlates and further highlight the
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importance of investigating these as distinct symptoms of AD. These initial findings may
also have implications for more specific and targeted treatment options for different
psychotic symptoms in AD.

4.2 Delusions in Alzheimer’s Disease
To investigate differences between AD patients that presented with symptoms of
delusions, we conducted two main analyses - PLS-CA and a binary logistic regression
analysis. Participants with available neuroimaging and GWAS data who presented with
symptoms of delusions and a control group of AD patients that did not, were included in
the PLS-CA. The binary logistic regression analysis included a significantly larger cohort
of participants that had structural imaging data, and unlike the PLS-CA was not limited
by GWAS availability. An important limitation to note for the PLS-CA, was that most, if
not all participants only completed the NPI-Q. The abbreviated questionnaire does not
distinguish between specific subtypes of delusions in AD. This is particularly relevant
because the two main subgroups – paranoid and misidentification delusions, may have
unique underlying correlates 154. Moreover, delusions of theft, which are the most
common subtype of delusions may be associated with memory impairments that arise as a
result of AD. The lack of information with regards to specific subtypes of delusions that
participants presented with may be a potential reason why we did not observe the
hypothesized effects with regards to interactions between neuroanatomical and genetic
factors.
In contrast, the binary logistic regression analysis identified a trend towards significance
for Components 2 and 3. Component 2 included frontal lobe structures such as bilateral
middle and lateral orbitofrontal, pars orbitalis, and frontal poles. Component 3 consisted
predominantly of temporal lobe structures including bilateral entorhinal cortex, amygdala,
parahippocampal, temporal poles, and the right insula. In particular, lower component
scores for Component 2 and higher component scores for Component 3 were associated
with an increased risk for delusions. These findings suggest that cortical atrophy of
frontal lobe structures and relative preservation of temporal lobe regions may be
necessary to generate symptoms of delusions in AD. This finding is consistent with the
hypofrontality model of delusions which postulates that impaired frontal lobe function,
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either arising from atrophy or hypometabolism, may be associated with the presence of
delusions in AD

57,155,156

. In support of this model, a SPECT study of patients with AD

and psychotic symptoms found that patients with delusions had hypoperfusion of the right
frontal lobe when compared to those without delusions 66. While another, through the use
of voxel-based morphometry, found that patients with AD and delusions when compared
to those without delusions had smaller grey matter volumes in bilateral parahippocampal
gyrus, right posterior cingulate, right orbitofrontal cortex, bilateral inferior frontal cortex,
right anterior cingulate, and left insula 157. Although in our study we did not identify
hemispheric lateralization with respect to delusional symptoms, the localization of these
symptoms to the frontal lobe are consistent with prior studies. Furthermore, studies that
directly assessed frontal lobe function through the use of cognitive rating scales found
that psychotic symptoms in AD were associated with impaired working memory as
measured by the digit span (forward and backward) task 158. One other study looking
specifically at frontal lobe function in patients with AD and delusions also found that
patients with AD and delusional thoughts had lower overall scores on the Frontal
Assessment Battery when compared to those without symptoms of delusions 159. Based
on the observed results, the authors hypothesized that impairments in executive
functioning and not just episodic memory deficits may be associated with delusional
thoughts. While the results of the binary logistic regression analysis showed a trend
towards significance in frontal lobe regions, it may also be important to consider how
other comorbid neuropsychiatric symptoms (i.e. depression, agitation, or apathy) may
influence the presence of misidentification and paranoid delusions either through
modulating attentional capacity or increasing susceptibility to paranoia.

4.3 Hallucinations in Alzheimer’s Disease
Results of the PLS-CA identified a trend towards significance for Component 1. In
particular, the interaction between smaller cortical thickness values in a number of
frontal, temporal, and parietal regions and SNPs in the glutamatergic system
distinguished those with hallucinations from those without. The glutamatergic system has
previously been implicated in the NMDA receptor hypofunctioning hypothesis of
schizophrenia which postulates that downregulation of glutamate signaling in prefrontal
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regions which project to subcortical structural such as the amygdala, nucleus accumbens,
and brainstem structures may lead to the development of positive symptoms 160–162. More
specifically, dysfunction in the cortical-brainstem circuitry arising from reduced
glutamate signaling can lead to excessive dopamine release in the mesolimbic pathway,
which can in turn result in hallucinations and delusions 163–165. A previous study has
similarly implicated a role of the GRIN2A receptor, in particular identifying an
association between the homozygous recessive genotype of rs9922678 in the GRIN2A
receptor and a bilateral reduction in hippocampal volume in patients with schizophrenia
166

. This finding is in line with the results of the PLS-CA which suggest that the

homozygous recessive genotype of res9922678 may be associated with reduced cortical
thickness in temporal lobe structures. This finding further supports our rationale that
regional brain atrophy arising from AD may unmask the effects of SNPs in
neurotransmitters systems. This is particularly relevant to approved medications that are
used to treat neuropsychiatric symptoms in AD, given that antagonism of the NMDA
receptor may actually contribute to the development of hallucinations in patients with
AD. For instance, Memantine is a non-competitive NMDA antagonist that is often
administered to patients with AD. This drug was designed to treat glutamate neurotoxicity
which arises as a result of excessive activation of glutamate receptors, which in turn can
lead to neuronal death. Although Memantine has been shown to have some benefits on
cognition and overall function, one of the most frequent documented side-effects of this
drug includes hallucinations in patients with AD 167–169. Given, the risk of hallucinations
that are associated with Memantine, not only is it important to address whether these
symptoms in AD are a result of the drug, but also the effect of this drug on patients with
existing genetic variants in NMDA receptors. Namely, whether the frequency and
severity of hallucinations may be exacerbated in patients with genetic variants in NMDA
receptors.
When considering the imaging data alone in the larger cohort, the logistic regression
results were slightly different than the PLS-CA. In particular, the PLS-CA identified only
regions that were smaller in those with hallucinations, while the binary logistic regression
analyses identified regions with cortical thickness values that were larger and smaller in
those with hallucinations when compared to those without. The main conflicting results
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between the PLS-CA and binary logistic regression involved regions of the parietal lobe
and the entorhinal cortex. Based on the PLS-CA these two regions were smaller in those
with hallucinations when compared to controls, while in the binary logistic regression
were larger in those with hallucinations, when compared to controls. The results of the
binary logistic regression analysis suggest that larger cortical thickness in parietal, postcentral, amygdala, cuneus, and entorhinal cortex regions and smaller cortical thickness in
the anterior cingulate may be associated with symptoms of hallucinations. One possibility
as to why these differences may exist may be consistent with our initial prediction. We
posited that atrophy is necessary for unmasking the effects of SNPs, which may explain
why the PLS-CA only identified ROIs that were atrophied in those with hallucinations
when compared to those without. In contrast, the binary logistic regression analysis,
which only looked at imaging variables in a larger sample, likely provides more
information with regards to regions that are relatively preserved in those with
hallucinations when compared to those without.
The findings from the logistic regression are in line with some previous studies in patients
with AD which suggest that relative preservation of parietal, temporal, and occipital
regions are necessary for the generation of hallucinations 87. This particular pattern of
frontal atrophy and preservation of temporal and posterior regions is also consistent with
the case reports of Schneider and colleagues (1961), who noted that following localized
lesions to the frontal lobe, patients who had suffered from previous falls or seizures
developed hallucinations in the temporal and occipital lobes. The authors postulated that
in this case abnormal activity was propagated along the uncinate fasiculus which connects
frontal regions like the orbitofrontal cortex to temporal lobe and limbic structures 170.
More specifically, it is thought that lesions in frontal regions which through the uncinate
fasiculus are connected to temporal lobe structures important for visual recall may lead to
abnormal firing from the frontal lobe to these temporal lobe structures to generate
symptoms of visual hallucinations. In future studies of psychosis in AD it would be of
interest to evaluate if those with a frontal-variant of AD would be more susceptible to
hallucinations, and to assess white matter connectivity, particularly tracts connecting the
frontal lobes to the parietal and temporal regions.
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The anterior cingulate itself also plays a key role in self-referential processing and
discriminating between self-generated and external information and has been implicated
in the generation of hallucinations in schizophrenia 171,172. A SPECT study of psychotic
symptoms in AD, also found that those with psychosis had lower regional perfusion in
frontal regions such as the dorsolateral frontal, anterior cingulate, as well as other parietal
and subcortical structures 173. Given the role of the anterior cingulate, we suggest that
atrophy of the anterior cingulate, which we identified in our study, may result in
misattribution of external stimuli to internal states thereby resulting in symptoms of
hallucinations. Importantly, the anterior cingulate also has extensive connections to
limbic structures, including the amygdala and the insula, and has also been shown to be
associated with the processing of negative emotions such as fear 174,175. When tying this
back to hallucination in AD, abnormal perceptions generated from inaccurate internal
representation of stimuli may lead to an increased fear response, and distress in those
experiencing hallucinations. This is particularly important given that this may be a
contributing factor to the increased rates of institutionalization of patients with AD and
hallucinations 82,83.

4.4 The Co-occurrence of Delusions and Hallucinations in
Alzheimer’s Disease
To investigate differences in patients with only delusions, only hallucinations, both
hallucinations and delusions, and patients with neither symptom, we conducted a PLSCA. The objective of this analysis was to try and identify differences that may exist on a
neuroanatomical and genetic level, between individuals who present with particular or
multiple symptoms of psychosis. Results of the PLS-CA identified a trend towards
significance for Component 1. Namely, the latent factor plot and bootstrap confidence
intervals suggest that those with hallucinations only (AD+H) and those with both
delusions and hallucinations (AD+DH) may have a unique pattern of interactions between
SNPs and ROIs. Although it is difficult to draw definitive conclusions given the small
cohort sizes, multiple comorbid psychotic symptoms may be associated with more
advanced cortical atrophy or simply a different pattern of cortical reorganization in
response to the cognitive deficits that arise from AD. Given the results of our study which
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suggest that patients with AD+DH have cortical thickness values below the grand mean
in the large majority of ROIs when compared to those with just hallucinations, we
speculate that disease severity may be driving the observed differences between the two
groups. One study that looked into the frequency of neuropsychiatric symptoms and AD
found an association between increasing frequency of delusions, hallucinations and
aberrant motor activity with increased disease severity 176. Although in our study the two
groups did not differ in disease severity, it could be that those with AD+DH, while having
more severe cortical atrophy, either have a different pattern of cortical reorganization or
are able to use alternative compensatory cognitive strategies which may mask the degree
of cognitive decline on clinical observation. Many studies that have described
hallucinations in AD have tended to group together hallucinations and delusions into one
overarching category of psychotic symptoms, which makes it difficult to parse underlying
differences that may exist between the two. The findings of our study highlight the
importance of investigating these symptoms as distinct phenomenon given the differences
that we identified in the AD+H and AD+DH cohorts.

4.5 Limitations and Future Directions
This study was limited by the small sample size of participants endorsing symptoms of
hallucinations and delusions. A replication cohort, potentially using individuals from the
ADNI-2 database, may allow us to draw more definitive conclusions about the different
interactions between brain regions and SNPs that may be associated with delusions and
hallucinations. Furthermore, because many of the SNPs that we investigated were
localized on the same chromosome, a haplotype analysis to detect SNPs that are in high
linkage disequilibrium (more likely to be inherited together), may allow us to reduce the
number of SNPs in our model and thereby increase the power of our study to detect
associations between brain regions and genetic factors. In future studies, where we are
powered to investigate more SNPs, it may be interesting to consider the interaction of
neuroanatomical factors and SNPs in the serotonergic system. A previous study
investigating the neuropathological and neurochemical correlates of psychosis in patients
with AD, found that on post-mortem analysis, patients with psychotic symptoms had
significantly reduced levels of serotonin in the prosubiculum and trends towards
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reduction of serotonin in middle frontal, temporal, entorhinal cortex, and hippocampal
regions 73. Additional information with regards to SNPs in the serotonergic system that
may be interacting with different brain regions may be of particular interest when
considering the effects of newer antipsychotic treatments in patients with AD. For
example, a newer drug by the name of Pimavanserin, a 5-HT2A inverse agonist, has been
approved in the United States for the treatment of hallucinations in patients with
Parkinson’s disease. This drug is now also being tested for efficacy in patients with
psychotic symptoms in AD. Early animal studies of this drug on psychotic symptoms in
rodent models of AD, found that administration of Pimavanserin reduced psychosisassociated behaviours such as head twitches, excessive locomotor activity, and also
normalized pre-pulse inhibition 177. More recent human studies, including a randomized,
double-blind, placebo controlled study investigating the efficacy of Pimavanserin in AD
patients with hallucinations and/or delusions found that patients on the drug demonstrated
significant improvements in psychotic symptoms when compared to those on placebo and
did not experiences negative cognitive effects 178. Given these findings, looking
specifically at SNPs in the 5HT2A receptor and their interaction with SNPs in other
neurotransmitter systems and brain regions, could provide us with more information on
the specific mechanism by which hallucinations and delusions arise in patients with AD.
Furthermore, this study was limited because we were unable to dissociate between the
specific subtypes of hallucinations and delusions within our cohorts. In future studies,
where we are able to distinguish between the subgroups, it may provide us with more
valuable information with regards to what particular subtypes of delusions or
hallucinations may be driving the results that we obtained in our analysis. Given our
findings of frontal lobe atrophy in patients with AD as well as frontal involvement in
patients with hallucinations, in future studies it may be important to more specifically
examine regions of hyper- and hypometabolism using fluorodeoxyglucose positron
emission tomography (FDG-PET). This is because MRI data is limited in detecting only
structural changes arising from regional cortical atrophy, which itself may not be easily
identified in earlier stages of AD. FDG-PET may be a more powerful tool in detecting
brain regions or networks that are abnormally hyper or hypo-active in response to
disrupted cortical signaling. This in turn, may allow us to better understand the cortical
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networks implicated in aberrant local and network-wide signaling which may give rise to
symptoms of hallucinations and delusions in AD. Identifying networks of brain regions
may then further guide diffusion tensor imaging studies to map white matter tracts that
may be implicated in the pathology of psychotic symptoms in AD. This will allow us to
better understand whether localized lesions to specific brain regions and/or connections
between brain regions may be associated with AD+P.

5

Conclusions

In summary, the results of our study provide preliminary evidence of a unique signature
of neuroimaging and genetic interactions which may be associated with the presence of
hallucinations in AD. Specifically, these results suggest that genetic variants in the
glutamatergic system, along with regional brain changes, may uniquely identify those
with hallucinations. Although the results of the PLS-CA did not identify any significant
differences in interactions between SNPs and ROIs, we did identify a trend towards
significance in the logistic regression analysis which suggests that atrophy to the frontal
lobe coupled with preservation of temporal lobe structures may be associated with
symptoms of delusions in patients with AD. These findings further suggest that there may
be distinct patterns of interactions that separate those with specific psychotic symptoms in
AD from those without. Overall, knowledge of the interactions between SNPs in
neurotransmitter systems and particular brain regions, may be an important starting point
for earlier detection of those who may be susceptible to these symptoms in AD, and may
allow for the development of more specific and targeted treatment options.
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Appendix
Appendix A. Complete list of regions of interest included in analyses
List of 82 Regions of Interest
ST110TA Right Precentral
ST51TA Left Precentral
ST74TA Right Caudal Middle Frontal
ST15TA Left Caudal Middle Frontal
ST115TA Right Superior Frontal
ST56TA Left Superior Frontal
ST84TA Right Frontal Pole
ST98TA Right Medial Orbitofrontal
ST114TA Right Rostral Middle Frontal
ST55TA Left Rostral Middle Frontal
ST25TA Left Frontal Pole
ST39TA Left Medial Orbitofrontal
ST116TA Right Superior Parietal
ST108TA Right Post Central
ST102TA Right Paracentral
ST57TA Left Superior Parietal
ST49TA Left Post Central
ST43TA Left Paracentral
ST118TA Right Supramarginal
ST90TA Right Inferior Parietal
ST59TA Left Supramarginal
ST31TA Left Inferior Parietal
ST32TA Left Inferior Temporal
ST40TA Left Middle Temporal
ST26TA Left Fusiform
ST58TA Left Superior Temporal

ST130TA Right Insula
ST111TA Right Precuneus
ST52TA Left Precuneus
ST104TA Right Pars Opercularis
ST62TA Left Transverse Temporal
ST121TA Right Transverse Temporal
ST72TA Right Bank Superior Temporal Sulcus
ST36TA Left Lateral Orbitofrontal
ST95TA Right Lateral Orbitofrontal
ST46TA Left Pars Orbitalis
ST105TA Right Pars Orbitalis
ST106TA Right Pars Triangularis
ST47TA Left Pars Triangularis
ST45TA Left Pars Opercularis
ST13TA Left Bank Superior Temporal Sulcus
ST34TA Left Isthmus Cingulate
ST24TA Left Entorhinal
ST83TA Right Entorhinal
ST103TA Right Parahippocampal
ST44TA Left Parahippocampal
ST14TA Left Caudal Anterior Cingulate
ST73TA Right Caudal Anterior Cingulate
ST54TA Left Rostral Anterior Cingulate
ST113TA Right Rostral Anterior Cingulate
ST50TA Left Posterior Cingulate
ST109TA Right Posterior Cingulate

ST119TA Right Temporal Pole
ST60TA Left Temporal Pole
ST117TA Right Superior Temporal
ST91TA Right Inferior Temporal

ST93TA Right Isthmus Cingulate
ST53SV Left Putamen
ST112SV Right Putamen
ST16SV Left Caudate

ST99TA Right Middle Temporal
ST85TA Right Fusiform
ST82TA Right Cuneus
ST23TA Left Cuneus

ST75SV Right Caudate
ST42SV Left Pallidum
ST101SV Right Pallidum
ST11SV Left Accumbens Area
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ST107TA Right Pericalcarine
ST48TA Left Pericalcarine
ST97TA Right Lingual
ST38TA Left Lingual

ST70SV Right Accumbens Area
ST12SV Left Amygdala
ST71SV Right Amygdala
ST61SV Left Thalamus

ST35TA Left Lateral Occipital
ST94TA Right Lateral Occipital

ST120SV Right Thalamus
ST17SV Left Cerebellum Cortex

ST129TA Left Insula

ST76SV Right Cerebellum Cortex
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